Rodent models of heart failure: an updated review

A. C. Gomes · I. Falcão-Pires · A. L. Pires ·
C. Brás-Silva · A. F. Leite-Moreira

© Springer Science+Business Media, LLC 2012

Abstract Heart failure (HF) is one of the major health and economic burdens worldwide, and its prevalence is continuously increasing. The study of HF requires reliable animal models to study the chronic changes and pharmacologic interventions in myocardial structure and function and to follow its progression toward HF. Indeed, during the past 40 years, basic and translational scientists have used small animal models to understand the pathophysiology of HF and find more efficient ways of preventing and managing patients suffering from congestive HF (CHF). Each species and each animal model has advantages and disadvantages, and the choice of one model over another should take them into account for a good experimental design. The aim of this review is to describe and highlight the advantages and drawbacks of some commonly used HF rodent models, including both non-genetically and genetically engineered models, with a specific subchapter concerning diastolic HF models.

Keywords Animal models · Rodents · Heart failure · Diabetes mellitus · Cardiovascular research

Introduction

Heart failure (HF) is a complex syndrome in which patients should present the following characteristics: symptoms of HF, signs of fluid retention and objective evidence of an

abnormality of the cardiac structure or function at rest [53]. It is often divided in two distinct entities, namely systolic heart failure (SHF) and diastolic heart failure (DHF) or, in alternative, HF with reduced ejection fraction and HF with preserved ejection fraction, respectively. Despite the hot controversy on the definition of each entity, SHF is characterized by an inability of the myocardium to contract and eject blood, while DHF refers to a disturbance in accommodating blood volume during diastole at low filling pressures, due to impaired ventricular relaxation (primarily affecting early diastole) or increased myocardial stiffness (primarily affecting late diastole) [152]. Besides defective myocardial relaxation, the mechanisms underlying DHF include abnormal extracellular matrix dynamics and altered myocyte cytoskeleton, which could interfere with the passive properties of the ventricular wall [152].

The great majority of animal models have been developed for SHF. Besides being rather difficult to replicate pure DHF in animal models, these are also more demanding and time-consuming than SHF. Therefore, not surprisingly most HF models developed so far represent SHF.

Non-genetically engineered rodent models

Pharmacologically induced cardiomyopathy

Doxorubicin

Doxorubicin (adriamycin, DOX) is an anthracycline widely used in cytostatic treatments. One of the major long-term consequences of DOX therapy is the development of cardiomyopathy and ultimately CHF in humans as in experimental animals. Therefore, understanding the pathogenesis

A. C. Gomes · I. Falcão-Pires · A. L. Pires · C. Brás-Silva ·
A. F. Leite-Moreira (✉)
Department of Physiology and Cardiothoracic Surgery, Faculty
of Medicine, University of Porto, Alameda Professor Hernâni
Monteiro, 4200-319 Porto, Portugal
e-mail: amoreira@med.up.pt

of cardiotoxic cardiomyopathy is essential to the development of new measures to prevent cardiotoxicity associated with antineoplastic therapies. DOX causes a dose-dependent cardiotoxicity and thus has been used to induce HF in various animal species [21, 37, 291, 293].

DOX administration once a week for 6 weeks or on alternate days for 2 weeks has been shown to induce cardiomyopathy and HF [51, 168, 284]. Interestingly, a single dose of DOX has been shown to induce significant left ventricular (LV) dysfunction in mice after 5 days [189]. This drug is usually administered by intravenous or intracoronary injection. The latter allows delivery of DOX at a smaller dose to induce HF without systemic toxicity [203].

DOX-induced cardiomyopathy is characterized by ventricular wall thinning and dilatation, and depressed systolic and diastolic function [22, 50, 168, 291] accompanied by fluid retention and by neurohumoral activation [8]. At the cardiac muscle level, DOX promotes intrinsic contractile dysfunction and reduced contractile reserve [21, 22, 50]. Furthermore, DOX impairs vascular [208] as well as endocardial [21] endothelial function and [27, 151, 287] induces inflammatory reactions in the heart, leading to thrombosis in the atria and myocarditis [27, 75, 78, 293].

Multiple pathways of anthracycline-induced cardiac cellular injury have been proposed such as the release of cardiotoxic substances, which subsequently accumulate in cardiomyocytes [185], the generation of free radical, lipid peroxidation, and suppression of DNA, RNA and protein synthesis [255, 276]. Other studies suggest that cardiotoxicity pathways include abnormalities in Ca^{2+} handling [50, 54, 285]; induction of mitochondrial DNA lesions [149]; degradation of myofilament and cytoskeletal proteins, including titin [160] and dystrophin [40]; interference with various pro-survival kinases [224]; and changes in adrenergic and adenylate cyclase function [33, 74]. These examples of a much larger set of proposed cardiotoxic mechanisms are not mutually exclusive: they may each contribute to cardiac cell damage, ultimately leading to myocyte death, by either necrosis or apoptosis [254]. Additionally, it was recently demonstrated that DOX cardiomyopathy can be also mediated by depletion of the cardiac stem cell pool and rescued by restoration of progenitor cell function [50].

Spontaneous hypertensive rats (SHR) are more sensitive to the toxic effects of DOX [98], probably because of the low free radical-scavenging ability of their myocardium [122].

DOX model has a short time course of induction of HF and also the advantages of being technically simple, reproducible, non-invasive and economical. Additionally, it can be used in several animal species to promote either chronic or acute HF [203]. The main limitations of this model are related to the variable degree of ventricular

dysfunction and the high incidence of arrhythmias that contribute to the high mortality rate. Anthracycline administration also has undesirable bone marrow, gastrointestinal and renal toxicities that can however be eliminated by the intracoronary injection of the drug [8, 203].

Homocysteine

Hyperhomocysteinemia has been identified as a causative factor of cardiac stress and dysfunction in both spontaneous hypertensive and normotensive rats [129, 130]. In rats, supplementation of diet with homocysteine for 10 weeks produces hyperhomocysteinemia and consequently ventricular dysfunction with compromised systolic and diastolic function [52, 130]. The main factors involved in the development of HF are oxidative stress and inflammatory mediators [129].

Isoproterenol

Excessive doses of catecholamines produce diffuse myocardial destruction with cardiomyocyte necrosis and extensive fibrosis in both animals and humans [219, 220, 292]. The mechanism underlying myocardial damage is likely related to an imbalance between oxygen supply versus demand due to myocardial hyperactivity [62]. In mice, infusion of isoproterenol for 7 days has been shown to induce cardiac dysfunction [216]. In rats, subcutaneous administration of isoproterenol for 3 days leads to a dose-dependent impairment of cardiac function and neurohumoral activation [88, 325], with cardiomyocyte necrosis and extensive LV hypertrophy and dilation and after 2 and 12 weeks, respectively [92, 324]. However, isoproterenol administration before ischemia exerts a cardioprotective effect in rats [92]. The advantages of this model are its technical simplicity and excellent reproducibility in association with a satisfactory low mortality. Nonetheless, it seems not suitable for inducing an overt state of CHF because higher doses of catecholamines can increase the mortality rate up to 80% [88].

Monocrotaline

Monocrotaline (MCT) is a plant toxin derived from *Crotalaria spectabilis* that can be administered by intraperitoneal, subcutaneous or intravenous injection to induce right ventricular dysfunction and HF within 4–6 weeks [30, 299]. Current hypotheses of the pathogenesis of MCT-induced pneumotoxicity suggest that MCT is transformed in a bioactive pyrrole metabolite in the liver and is then transported by red blood cells to the lung, where it initiates endothelial injury. The metabolite has a half-life of ~3 s in aqueous media and primarily affects the pulmonary

vascular bed as lungs are the first major vascular bed after the liver [230]. Nonetheless, MCT can injury other structures such as liver [135] or kidney [262]. In the pulmonary vasculature, MCT induces perivascular inflammation, platelet activation and endothelial dysfunction, generally leading to increased pulmonary arterial pressure. These changes are accompanied by increase in RV systolic and diastolic pressures, hypertrophy and ultimately HF [99, 310]. Besides inducing HF, MCT is a simple model which, at an earlier phase, shares some similarities with human pulmonary hypertension.

Myocardial infarction-induced HF

Since ischemic heart disease is the most important cause of human HF, coronary artery occlusion is the most common method of inducing acute myocardial damage in animal models. Ligation of the left anterior descending (LAD) coronary artery or one of its branches remains the most preferred and acceptable method of inducing regional injury and subsequent HF in rodents [10, 85], as well as to gain further insight into pathophysiology of post-myocardial infarction (MI) cardiac remodeling [12, 223]. The mechanisms responsible for cardiac remodeling are mostly related to changes in extracellular matrix of the remaining overloaded myocardium and neurohumoral activation [72, 156, 234].

Surviving mice gradually develop HF within the 4 weeks following the surgical procedure [76, 155, 158]. In rats, a significant decrease up to 25% in cardiac output is observed 8 weeks after LAD ligation [115]. The infarct size varies significantly (between 10 and 45%) and is directly related to the degree of LV function impairment [228], influencing the time course of CHF development [10]. Generally, the infarct extension needs to affect at least 30% of the LV mass in order to present the typical characteristics of CHF and to induce considerable increases in the molecular markers of hypertrophy [10]. Age also exerts a noteworthy effect on the time course of CHF development, with young animals tolerating well LAD ligation without CHF signs, in spite of the larger infarct size [85]. Some recent studies showed that female mice undergo less extensive ventricular remodeling, suggesting the influence of sex hormones as a putative explanation for gender differences [315].

In both mice and rats, mortality ranges between 35 and 50% and occurs within the first hour after MI due to ventricular fibrillation and severe acute HF [79, 144]. Furthermore, in rats, it seems to be strain dependent with Lewis inbred rats surviving more than Sprague–Dawley rats [164].

Contrary to the clinical situation, in which the patient has progressive non-occlusive coronary artery obstruction,

myocardial infarct in this model is due to the sudden occlusion of a normal coronary artery. Therefore, efforts have been made to create a model of chronic myocardial ischemia, more similar to the clinical reality. Indeed, a mice model of hyperlipidemia and atherosclerosis with multiple infarction and CHF has been described. However, those high-density lipoprotein receptor SR-B1 and apolipoprotein-E double knockout mice survive only few weeks after birth limiting their use in HF research [23].

Protocols of temporary LAD occlusion have been developed to reproduce human ischemia–reperfusion injury. This model has confirmed the benefits of reperfusion since infarct size was found to be significantly lower than after permanent occlusion of the coronary artery. However, they also revealed the diversity of results as a consequence of mouse left coronary anatomic high variability [187].

The procedure was further modified to analyze ischemic preconditioning of the heart. In this method, LAD is repeatedly occluded to subject the heart to several rounds of brief ischemia and reperfusion before permanent occlusion. Molecular analyses identified various ischemia-induced genes that confer tolerance to subsequent ischemic event [311].

The cost and simplicity confer important advantages to LAD ligation. On the other hand, rat differs from human in terms of electrophysiology, coronary circulation, cardiac protein isoforms and time course of MI evolution. In fact, available data point to a faster onset of healing and termination processes in rats [142], which mean results must be interpreted with caution.

An alternative model of MI was cryoinfarction, which induces a series of cryoinjuries in the epicardium of mice and rats [245]. However, it has not caught the interest of the scientific community, and thus, it is no longer used.

Myocarditis-induced HF

Viral myocarditis is a common cause of dilated cardiomyopathy and HF. The coxsackie-B3 virus (CB3) and the encephalomyocarditis virus (EMCV) have been used to induce myocarditis in rodents [102, 213, 318]. EMCV infection can lead to myocyte necrosis and significant biventricular dilation during the phase of viremia, while typical signs of CHF appear after 7–14 days of virus inoculation [68, 177, 213]. This model is limited to Balb/c and DBA/2 mice because other mouse strains are resistant to virus infection [306]. Virus inoculation in genetic engineered mice has been shedding light on the molecules involved in the pathogenesis of viral myocarditis. Indeed, the administration of an exogenous antitumor necrosis factor- α (anti-TNF- α) antibody reduced myocardial lesion and improved survival, mitigating the effect of the

observed increase in TNF- α expression [178]. A retrovirus model of encephalitis and myocarditis in mice showed that nuclear factor- κ B activation confers protection against virally mediated apoptosis and its expression is preserved in the presence of interferon- β . The absence of any of these molecules in the myocardium leads to striking viral infection and cell death [214]. Transgenic knockout models of components of the immune system have provided interesting insights in the pathogenesis of viral myocarditis [163].

Another pathogenic agent capable of causing myocarditis and dilated cardiomyopathy is the protozoan parasite *Trypanosoma cruzi*, which causes Chagas disease, a major form of HF in Latin America [46]. The infection causes generalized vascular inflammation, which stimulates the production of endothelin-1 and thromboxane-A₂, further enhancing coronary vasospasm and myocardial ischemia [35].

Autoimmune myocarditis has been induced by an immunization process with different intracellular antigens. In rats, hemodynamic deterioration and myocarditis have been reported after 3 weeks of immunization with cardiac α -myosin or α -myosin peptides [173, 305]. This was associated with increased expression and activity of inducible nitric oxide synthase (iNOS) and an inhibitor of that enzyme effectively attenuated the histopathologic changes, thus pointing to a relevant pathophysiologic role of nitric oxide (NO) [103, 104]. In mice, immunization with a monoclonal anti-dog SERCA2a antibody caused myocarditis [93].

Immunization of mice with recombinant murine cardiac troponin I (mcTnI) resulted in myocardial deposition and elevated serum levels of anti-mcTnI autoantibodies, accompanied by myocardial inflammation (both humoral and cellular immune response), cardiac dilatation, contractile failure and increased mortality rate [83].

Systemic hypertension-induced HF

Spontaneously hypertensive rats (SHR)

Systemic hypertension is another relevant factor in human CHF. Spontaneous hypertension is a natural model of pressure overload, in which systemic hypertension leads to HF with aging. Hypertensive vascular lesions appear within 6–7 weeks, being more severe in males than in females. For the first 12 months, the hypertrophy is compensated and contractility is preserved, but after 18–24 months, there is overt CHF characterized by fibrosis, LV dilation and reduced systolic function [13, 100, 226]. These structural and functional changes occur in tandem with a marked rise in cytokine levels such as TNF- α and interleukin-6 [223]. Transition to failure has

been suggested to depend on significant alterations in the expression of genes encoding extracellular matrix proteins, oxidative stress and increased apoptosis of myocytes [1, 13, 15, 157, 273]. The gradual onset of hypertension with aging makes this model suitable for studying the transition from hypertrophy to CHF and for reproducing hypertension-induced CHF in humans [194]. It has the advantage of avoiding the complications associated with surgical or pharmacologic interventions, while mimicking the changes found in human essential hypertension [16, 19]. Nonetheless, the long period required for developing CHF poses a great limitation, making it a time-consuming and consequently an expensive model. Additionally, this model has other two relevant drawbacks, namely the absence of an appropriate control and the complexity of the genetic mutations, which have affected not only blood pressure but many other regulatory systems as well.

The SHR stroke prone (SHR-SP) is a further developed substrain with even higher levels of blood pressure and a strong tendency to die from stroke [319].

Spontaneously hypertensive HF-prone rats (SHHF)

Spontaneous hypertensive rats carry the *facp* corpulent gene, which encodes a defective leptin gene, and therefore, they develop obesity and HF [41, 188]. The time for the development of HF depends on *facp* gene dosage and gender (male animals are more prone to HF than females [96]) but, in general, SHHF rats present HF earlier than the SHR strain, with loss of cardiac function starting at the age of 15 months [100]. These animals present alterations in the renin-angiotensin-aldosterone system (RAAS) and also in calcium metabolism [82, 107, 188, 222]. The greatest advantage of this strain is the possibility of studying drug interventions in an extended range of cardiovascular risk factors like obesity, diabetes and renal dysfunction [259].

Dahl-salt-sensitive rats

This is a mutant strain of Sprague–Dawley rats that are characterized by hypersensitivity to sodium intake [48]. When placed on a high-salt diet from the 6th week of age, they develop concentric LV hypertrophy without chamber dilation around the 11th week and decompensate HF with marked ventricular dilation between the 15th and the 20th week [119, 139]. Failure is associated with reduced myocardial performance as evidenced by the lower performance of muscle strip preparations and the short lifetime of failing rats [119]. Diastolic dysfunction, as well as increased LV endothelin-1 production, collagen accumulation and even survival could be improved more effectively by a combination of angiotensin receptor blockers

and angiotensin-converting-enzyme (ACE) inhibitors than either agent alone [137].

Interestingly, it has been shown that introducing high-salt diet at 7 or 8 weeks of age can result in distinct HF phenotypes. Indeed, the 7-week starting rats showed a steep elevation in blood pressure and progressive LV hypertrophy, falling into overt DHF at approximately 19 weeks. On the other hand, the 8-week starting rats showed a gradual rise in blood pressure and less progressive LV hypertrophy, developing SHF at approximately 26 weeks. Therefore, these two different models of overt HF may be useful as models of isolated DHF and SHF based on the same hypertensive heart disease, which could be relevant to the pathophysiologic and molecular characterization of each HF subtype [55]. Another report found that the development of HF was dissociated from changes in passive diastolic and active systolic properties, suggesting that volume overload plays an important pathophysiologic role in the development of HF despite preserved overall ventricular pump function in this model of chronic hypertension [139].

This model is suitable to study the transition from compensated hypertrophy to failure. Moreover, it is often used to identify the role of several pathways and molecular mechanisms like oxidative stress, extracellular matrix degradation [289], calcium handling impairment [253] as well as redox-regulated transcription factors [116] and apoptotic factors activation [320].

DOCA-salt rats

The deoxycorticosterone acetate (DOCA) salt-induced model of hypertension is a typical representative of pharmacologically induced hypertension. A very high subcutaneous dose of DOCA is required to induce hypertension in rats [268]. Isotonic saline is the sole drinking fluid, which hastens and aggravates progression to hypertension [280]. Despite being salt-dependent in its initiation, this model frequently needs surgical reduction of renal mass or unilateral nephrectomy. DOCA-salt hypertension is a low renin and volume-overloaded form of hypertension. The combination of DOCA-salt and unilateral nephrectomy results in hypertension, renal hypertrophy, nephrosclerosis, cardiac hypertrophy and myocardial and perivascular fibrosis within 4–5 weeks of chronic treatment [89, 215].

The pathophysiologic mechanisms underlying the development and maintenance of DOCA-salt hypertension include increased levels of arginine vasopressin [120], angiotensin-II/aldosterone [300, 313], endothelin [179, 204, 258, 302] and oxidative stress [154, 175], excessive activation of the sympathetic nervous system [132] and nitric oxide synthase (NOS) uncoupling due to oxidative depletion of its cofactor tetrahydrobiopterin (BH4) [274]. Indeed, both inhibition of the angiotensin-aldosterone

system and endothelin receptor blockade have been shown to prevent cardiac remodeling, even without concomitantly reducing arterial blood pressure [89, 257]. Of notice, PPAR- α activation has also a beneficial effect on myocardial fibrosis and prevented diastolic dysfunction in DOCA-salt rats by modulation of NF- κ B inflammatory pathway [215]. Nonetheless, the cardiac consequences are minimal during the development of DOCA-salt hypertension-induced hypertrophy [29]. This is in contrast to the decreased responses reported in other rat models of cardiac hypertrophy and in the failing human heart. Therefore, hypertrophy in hearts of DOCA-salt hypertensive rats does not produce similar changes to the failing human heart [29].

Of notice, a group recently published a mouse model that combines a surgical intervention to induce pressure overload, namely transverse aortic constriction (TAC), with DOCA administration, in the setting of normal-salt diet. Compared with TAC mice, TAC plus DOCA mice had similarly normal LV systolic pressure and fractional shortening but more hypertrophy, fibrosis and diastolic dysfunction with increased lung weights, consistent with HF with preserved ejection fraction. There was progressive activation of markers of oxidative stress but no evidence of classic mineralocorticoid receptor-dependent gene transcription. Therefore, they suggest that pressure-overload hypertrophy sensitizes the heart to mineralocorticoid excess, promoting the transition to DHF without activation of the classic mineralocorticoid receptor-dependent gene transcription.

The major limitations of the DOCA-salt model are (1) the need to employ a large amount of drug, (2) the requirement for surgical reduction of renal mass and (3) the dependence on a strictly controlled ingestion of a high NaCl dose. On the other hand, its chief advantage is the potential to investigate the role of sodium in the developmental stages of hypertension.

2K1C rat

Since 1934, when Goldblatt and his co-workers induced an elevation of blood pressure by partial constriction of the renal artery of the dog [81], many successful models of renal-induced experimental hypertension have been developed in rats. In general, the procedure includes two-kidney Goldblatt hypertension (constriction of one renal artery while the contralateral kidney is left intact) and one-kidney Goldblatt hypertension (one renal artery is constricted and the contralateral kidney is removed) [280]. Clipping one renal artery, while leaving the contralateral kidney untouched, induces systemic hypertension and LV concentric remodeling within 8 weeks [131]. Histologic studies revealed extensive LV fibrosis, while echocardiography and hemodynamic data consistently shown diastolic dysfunction [131]. Indeed, inhibition of matrix

Fig. 1 Timeline progression of transverse aortic constriction: comparison between mice and rat

metalloproteinase activity in these hypertrophic hearts has been shown to provide beneficial effects in terms of structure and function [237]. At cellular level, several changes in the energy metabolism, actin–myosin cross-bridge cycle and protein expression were identified in renovascular hypertensive rats [131]. In addition, the paramount role of activation of the RAAS [73, 150] and the sympathetic nervous system [32, 270] has been thoroughly studied. In the one-kidney model, no compensatory increase in sodium and water excretion can occur, and hence, fluid volume is retained, which means this model is thus a sodium-fluid volume-dependent model. Therefore, it would be advantageous for studying the role of volume expansion in the development of hypertension [11]. During the early developmental stage, when the clip is removed, arterial blood pressure returns to normal in both models, suggesting that renovascular hypertension is both reversible and reproducible [147].

Pressure-overload-induced HF

Aortic constriction (banding) is a well-established surgical technique for induction of LV chronic pressure overload and hypertrophy in rodents. The banding initially imposes little or no restriction to aortic flow but gradually, as the animal grows, the relative severity of the constriction increases, resulting in cardiac hypertrophy. Aortic banding in several positions has been used to mechanically reproduce the cardiac consequences of aortic stenosis, systemic hypertension and coarctation of the aorta [111, 138, 203, 240, 279]. The constriction can be thoracic, either close to the origin of the aorta, ascending aortic constriction (AAC), or in the aortic arch between the first and second trunks and named transverse aortic constriction (TAC). Alternatively, the constriction can be performed in abdominal aorta, either below or above the renal arteries, the latter inducing hypertension by renal hypoperfusion and concomitantly LV hypertrophy [34]. The anatomic location of the constriction is the main responsible for the differences between these models. In this context, AAC is generally used to study the effects of early insult due to pressure overload, while TAC and suprarenal aortic constriction display a more gradual rise of pressure, progression toward hypertrophy and HF [16].

The timeline of disease progression depends on the selected species, age or gender, with mice subjected to TAC presenting LV hypertrophy as early as 7 days [294] and decompensate HF at 4 weeks [153], while rats present slower progression [16], as illustrated in Fig. 1. For instance, in weanling rats [70, 263, 309, 316], a TAC surgery that reduces 50% of the aorta diameter creates a systolic pressure gradient of ~50–60 mmHg between the aorta and the LV, inducing clear echocardiographic evidence of LV hypertrophy, and increases left atrial pressure around the 8th week [162]. After 18–20 weeks of compensated LV hypertrophy, a subgroup of animals eventually decreases LV systolic pressure, accompanied by increased LV volume, reduced ejection fraction and clinical signs of overt CHF [309]. Moreover, molecular changes have been reported with increased expression of β -myosin heavy chain, atrial natriuretic peptide (ANP), interleukin-1, interleukin-6 and TNF- α [200]. On the other hand, the failing myocardium exhibits a reduced expression of SERCA2a when compared to non-failing hypertrophied heart, which suggested that decreased levels of SERCA2a could be a marker of transition from compensatory hypertrophy to failure in these animals [70].

Abdominal aortic banding in rats causes an initial increase in contractility due to the compensatory activation of the sympathetic nervous system [25] but after 8 weeks, systolic and diastolic dysfunction as well as concentric hypertrophy are evident [34, 67]. In mice, suprarenal abdominal aortic banding causes cardiac hypertrophy within 4 weeks as a compensatory response, which eventually leads to CHF after 15–21 weeks depending on the degree of constriction as well as animal age, gender and weight [94, 312]. Changes in NO pathway are believed to play an important role in the pressure-overloaded heart and pathologic cardiac remodeling. In fact, reports showed that phosphodiesterase-5 (PDE5) inhibitor sildenafil reduces LV hypertrophy and dilation in the mouse TAC model [223, 290]. However, the most promising therapeutic approach is represented by a new neutral sugar organic nitrate, LA-419, the thiol group of which seems to protect NO from degradation, thereby increasing its bioavailability. In the aortic stenosis model, LA-419 has been found to restore the complete NO signaling cascade and reduce LV remodeling, but without restoring the original pressure

gradient, indicating a possible direct antiproliferative effect [243]. Additionally, the exogenous administration of the NOS cofactor BH4 has been shown to reduce LV hypertrophy, fibrosis and cardiac dysfunction in mice with pre-established pressure overload. In this setting, BH4 recoupled endothelial NOS, with subsequent reduction of NOS-dependent oxidative stress and reversal of maladaptive remodeling [195, 196].

Among the major advantages that these banding models share compared to other hypertensive or HF models is the ability to manipulate the degree of pressure overload by changing the constriction severity [197]. Concerning the thoracic aorta constrictions, the main advantage is the similarities to human HF progression, especially to aortic stenosis patients. Accordingly, it is characterized by initial compensatory phase, with concentric LV hypertrophy followed by an enlargement of cardiac chambers associated with a further deterioration of LV function [16]. Another advantage is the extensive information regarding TAC model: it was first described in 1994 by Rockman [240], and it has been extensively used since then, especially in mice either by traditional thoracotomy approach [67, 239] or by minimally invasive aortic banding through a small incision in the proximal sternum [111]. Finally, this method permits the quantification of the pressure gradient across the aortic constriction and the stratification of LV hypertrophy [223]. However, the rat TAC model has several drawbacks such as prolong duration of the protocols (Fig. 1), inter-individual variability in the response to pressure overload [198] and high proportion of debanding due to internalization of the constriction knot [171]. These two last disadvantages require the use of large experimental groups and the use of accessory methods for visualization of the constriction integrity and progression of disease, such as echocardiography. Both AAC and TAC models have a common disadvantage resultant from the complex surgical method and equipment necessary for open-chest microsurgery. The lack of such an extended learning curve is the major advantage of abdominal constriction model, alongside with the low mortality rate associated with banding (10%) [70]. Activation of RAAS might however limit the use of abdominal aorta constriction in some studies [241]. Moreover, decrease of LV relaxation rates makes such models valuable for the evaluation of diastolic dysfunction, which is an important factor in the progression of LV failure [69]. In addition, the stimulus for HF is gradual in onset as is the progression from compensated hypertrophy to HF in humans, thus making it clinically more relevant. Recently, a minimally invasive murine model of TAC debanding was described, in which it is possible to remove the band up to 4 weeks later through the same suprasternal incision [278]. This reversible model of pressure overload turned out to be an

interesting model to study the molecular mechanisms involved in LV reverse remodeling.

Volume-overload-induced HF

Arteriovenous shunts have been used to induce volume overload and consequently dilated cardiomyopathy and HF in rodents. Femoral artery to femoral vein fistulas lead to HF, but present a reported mortality above 25% in all studies [217]. The more recent aortocaval shunt is a relatively simpler and faster alternative to induce HF with good survival rates and no need to perform thoracotomy [28, 77, 231]. In rats, significant cardiac hypertrophy develops 4 weeks after shunt induction, with compromised LV contractility and increased end-diastolic pressure [256]. Severe volume overload from a large aortocaval fistula initially leads to depressed LV function followed by a compensatory hypertrophy and near normal function at 4 weeks [165, 307]. Decompensated hypertrophy or CHF develops between 8 and 16 weeks after the intervention and is characterized by a decline in systolic and diastolic function [34, 308] and a shift between myosin heavy chain isoforms expression [307]. Nonetheless, shunt closure has been reported in 7% of the cases, which means that it is necessary to confirm the patency of the shunt at the end of investigation. Of note that, not only the duration, but also the size of the shunt will determine the onset and severity of CHF in rats, with elevation of LV end-diastolic pressure reported only in the overt CHF group caused by a large shunt for a minimum period of 4 weeks [148]. This procedure has the advantage of being fast and usually well tolerated, despite the limitation of requiring a laparotomy.

Another procedure used to induce volume overload in rats is aortic valve regurgitation, in which an aortic valve cusp is punctured [56, 207].

The neurohumoral activation of volume-overload models includes local activation of RAAS, which is associated with depressed myocardial function [211]. Recent reports found that ANP expression is a more sensitive marker of volume overload than pressure overload [36]. In addition, long-term overexpression of SERCA2a in this animal model can preserve systolic function and potentially prevent diastolic dysfunction and LV remodeling [134].

Diabetic cardiomyopathy-induced HF

Animal models have been extensively used in diabetes research. Their utility can be questioned due to species differences; however, rodent models share many features with human diabetic cardiomyopathy. For example, rodent models of obesity, insulin resistance and type 2 diabetes present LV hypertrophy, diastolic dysfunction, increased cardiac fatty acid uptake and utilization, decreased cardiac

efficiency, impaired mitochondrial energetics, increased myocardial lipid storage, and impaired Ca^{2+} handling [4, 19, 31].

There are a number of pharmacologic rodent models of diabetes: streptozotocin (STZ) administration to rats or mice, which induces diabetes mellitus (DM) as soon as 48 h post-injection [295]. This substance is selectively toxic to β -cells in the pancreatic islets, induces insulin deficiency and hyperglycemia and therefore represents a model of type 1 diabetes.

On the other hand, selective inbreeding has produced several strains of animal that are considered reasonable models of type 1 diabetes, type 2 diabetes and related phenotypes such as obesity and insulin resistance (Table 1). Apart from their use in studying the pathogenesis of the disease and its complications, all new treatments for diabetes, including islet cell transplantation and preventive strategies, are initially investigated in animals. In recent years, a large number of new genetic animal models for the study of diabetes, including knock-in, generalized and tissue-specific knockout mice, have been described. Rodent models of type 2 diabetes include the Zucker fatty rat, as well as db/db and ob/ob mice, all of which display dysfunctional or absent leptin homeostasis and therefore develop insulin resistance in different timepoints.

In vivo studies in these rodents have revealed susceptibility to systolic and diastolic dysfunction using echocardiography and hemodynamic measurements [301]. They also exhibit a propensity to ischemia/reperfusion injury following LAD ligation, which occurs in conjunction with structural and functional changes to the LV [87]. However, there are several limitations when comparing these models to human diabetic cardiomyopathy, as spontaneous ischemia and atherosclerotic disease are not prominent in rodents [18]. The latter becomes simultaneously a valuable aspect as the effects of obesity, insulin resistance and diabetes on the heart can be studied independently of coronary artery disease [121]. Importantly, rodent models present fulminant and uncontrolled hyperglycemia or insulin resistance, while in the clinical setting patients with diabetes are increasingly well controlled as demonstrated by a recent study which found no evidence for diabetic cardiomyopathy in well-controlled patients with type 1 diabetes [141]. Moreover, because DM develops at varying stages in these models, it is important to keep in mind that studies performed in animals before the onset of diabetes may reflect changes that are secondary to the underlying obesity and insulin resistance, and studies performed after the onset of diabetes may reflect the added effects of hyperglycemia of different durations.

In conclusion, each model has certain limitations and no perfect model exists that exactly mimics human diabetic cardiomyopathy (Table 1).

Diastolic HF models

In spite of the rising prevalence of DHF, currently there is no evidence-based treatment strategies capable of changing its natural history, reflecting our poor understanding of this HF subtype [314]. Therefore, animal models of diastolic dysfunction and DHF urge for the development and pre-clinical evaluation of new effective therapies for this disease. However, animal models of DHF are rather scarce, thus leading to the utilization of diastolic dysfunction models, which are more widely published and very similar regarding the basic pathophysiologic mechanisms [60]. Furthermore, these models have been most commonly created in large animals, such as canine, sheep and swine. Nonetheless, there have been some successful rodent models that deserve to be highlighted in this review.

Animal models have tried to reproduce the paramount risk factors typically associated with diastolic dysfunction and DHF, namely aging, diabetes mellitus and hypertension [327]. In fact, the alterations in myocardial relaxation and stiffness associated with chronic hypertension and diabetes have been already mentioned above in the appropriate models, namely Dahl-salt-sensitive rats, DOCA-salt rats and diabetic cardiomyopathy.

Despite the great difficulty in developing an animal model of DHF age-induced, a recent study has characterized a model demonstrating isolated diastolic dysfunction associated with accelerated aging [235]. This mouse model is a spontaneous senescence model that displays many common geriatric disorders in the human population and recapitulates diastolic dysfunction as it naturally occurs in the elderly. Diastolic dysfunction, accompanied by fibrosis and an increase in pro-fibrotic cytokines, develops between 3 and 6 months of age, which is an early timepoint in the life span of these animals. This suggests that the physiologic abnormality manifests over a relatively short period of time and, from an experimental standpoint, adds an advantage as it allows for a more rapid study of pathophysiologic mechanisms. The senescence-accelerated mouse model will probably turn to be a useful model for future studies of age-related diastolic dysfunction, since the better insight into its underlying mechanisms could pave the way for designing specific pharmacologic strategies to prevent or treat this pathology [235].

The association between aging and diastolic dysfunction had already been addressed in a previous study, which compared adult (6-month-old) and old (24-month-old) Fischer 344/BNF1 rats after either 12 weeks of treadmill training or normal sedentary cage life [26]. Echocardiographic indices of LV relaxation were significantly lower in the old rats, but with training, they increased back to the levels seen in the adults. LV stiffness measured in isolated perfused hearts was not affected by age or training, but

Table 1 Summary of the characteristics of the most usual diabetes mellitus animal models

Model	Type	DM type	Species	Pathophysiologic changes	Advantages	Disadvantages	Ref.
Alloxan	P	1	Mouse Rat	Significant hyperglycemia Ketosis and/or ketoacidosis Glycosuria, hyperlipidemia, polyphagia, polydipsia Neuropathy and cardiomyopathy	Fast, economic and consistent	High mortality rate Alloxan has a very short half-life (<1 min) Hyperglycemia frequently reverts by pancreatic regeneration	[236]
Streptozotocin	P	1	Mouse Rat	Significant hyperglycemia Polyuria, polydipsia Muscular atrophy Neuropathy	Fast, economic and consistent	High mortality rate Very severe model	[232]
OLETF—Otsuka Long- Evans Tokushima Fatty	G	2	Rat	Hyperglycemia Polyuria, polydipsia Mild obesity Diastolic dysfunction Diabetic nephropathy with nodular glomerulosclerosis (30 wk)	Progressive DM: Initial phase (0–9 wk): Pancreatic islet hyperplasia and lymphocytes' infiltration Intermediate phase (10–40 wk): Pancreatic islet fibrosis Advanced phase (>40 wk): pancreatic islet atrophy. Type 1 DM	Late DM development Only males develop DM	[133]
ZDF—Zucker Diabetic Fatty	G	2	Rat	Dysfunctional leptin receptor Hyperphagia, hyperlipidemia, hyperglycemia Glucose intolerance and hyperinsulinemia (10–12 wk) Mild hypertension and obesity Decreased GLUT4 expression (25–55%) Impaired cardiac contractility and diastolic function (~ 20 wk) Increased LV mass and fatty acid oxidation	Very common model ZDF were selectively bred from Zucker fatty rat, which are similar but without hyperglycemia	Hydronephrosis Due to different genetic backgrounds, no comparisons can be made between ZDF and Zucker fatty rats	[125]

Table 1 continued

Model	Type	DM type	Species	Pathophysiologic changes	Advantages	Disadvantages	Ref.
GK—Goto-Kakizaki	G	2	Rat	Mild fast hyperglycemia Hyperinsulinemia and insulin resistance Decreased insulin production Retinopathy, microangiopathy, neuropathy and nephropathy	Stable degree of glucose intolerance Useful for studying advanced diabetic nephropathy Wistar rats are the control group	Non-obese	[84]
Wistar Fatty	G	1/2	Rat	Hyperglycemia, hyperlipidemia, hyperinsulinemia (12 wk) Glucose intolerance and insulin resistance Hypertension (16 wk) Wistar × Zucker selective breeding	Wistar rats are the control group	Only males develop type 2 DM Not commercially available	[136]
Db/db	G	2	Mouse	Leptin receptor deficiency Hyperlipidemia and obesity (8 wk) Polyphagia, polyuria and polydipsia Hyperglycemia (8 wk) and hyperinsulinemia (2 wk) Peripheral neuropathy Diabetic cardiomyopathy Impaired diastolic function, mitochondrial energetic, Ca^{2+} homeostasis and cardiac efficiency Increased LV mass, fatty acid oxidation and RAAS activation	Advantages associated with mice reduced size (see text)	Glucose levels progressively increase until the 16th week	[38]

Table 1 continued

Model	Type	DM type	Species	Pathophysiologic changes	Advantages	Disadvantages	Ref.
Ob/ob	G	2	Mouse	Leptin deficiency Hyperphagia and obesity (4 wk) Hyperglycemia and hyperinsulinemia (15 wk, following obesity) Insulin resistance and glucose intolerance Impaired diastolic function, mitochondrial energetic, Ca^{2+} homeostasis and cardiac efficiency Increased LV mass, fatty acid oxidation and lipid content	Advantages associated with mice reduced size (see text) Allows the evaluation of the early effects of obesity and insulin resistance on cardiac function and the effects of additional hyperglycemia at older ages	Certain degree of infertility Reduced metabolism and hypothermia	[118]
Pancreatectomy	S	1	All	Mild hyperglycemia No weight or insulin levels reduction	Useful for pancreatic regeneration studies Can be used in all animal model species Avoids pharmacologic toxicity of DM induction drugs Similar to type 2 DM due to pancreatic degeneration	Risk of infection Post-operative precautions Digestive complications	[186]
High-fat diet C57BL/6J	HFD	2	Mouse	Leptin and insulin resistance Hyperphagia and obesity Hyperglycemia and hyperinsulinemia (following obesity) Glucose intolerance Cardiac dysfunction (20 wk)	Advantages associated with mice reduced size (see text) Present many genetic and environmental features of the human disease High-fat diet C57BL/6J mice change myocardial substrate utilization prior to obesity and severe insulin resistance Useful for pharmacologic tests	Reduced metabolism and hypothermia Long high-fat diet period Mild hyperglycemia	[281]

G genetic model, *HFD* high-fat-diet model, *P* pharmacologic model, *S* surgical model, *wk* week

increased more rapidly during low-flow ischemia in the old hearts than in the adults. Again, training eliminated this age-associated difference in the response to ischemia, although it was not ascertained if the improvement was due to reversal of aging consequences or superimposition of some other effects. These findings indicate that in rats some age-associated changes in diastolic function are reversible and thus may not be intrinsic to aging but instead secondary to other processes, such as deconditioning [26].

Syrian cardiomyopathic hamster

The Syrian cardiomyopathic hamster is an established animal model for genetic cardiomyopathy, which has been extensively used since it was firstly described in 1962 by Homburger et al. [109]. They characterized an inbred line of Syrian hamster named BIO1.50 that experienced both cardiomyopathy and muscular dystrophy with 100% penetrance and [109] present an autosomal recessive mode of transmittance [109], thus being very useful for studying both cardiac and skeletal muscle disorders. Afterward, selective crossings gave rise to a new line, BIO14.6, which is now more widely used throughout the world [110]. Indeed, hitherto several cardiomyopathic hamsters (CM hamsters) have been derived from BIO14.6. Jasmin and colleagues established a new inbred line of UMX7.1 by cross-breeding BIO14.6 with unrelated healthy hamsters [126]. Later, another substrain of these hamster was isolated, the J2N [210]. The descendants of BIO14.6 and UMX7.1 were named as CHF146 and CHF147, respectively, and have been maintained at Canadian Hybrid Farms in Nova Scotia, Canada [113]. All the five CM hamsters (BIO14.6, UMX7.1, J2N, CHF146 and CHF147) develop an identical cardiomyopathy, progressing through pre-necrotic, necrotic, hypertrophic and dilated stages [108]. Therefore, the disease progression in the hamster parallels the human genetic disease [66].

The most remarkable genetic manipulation of CM hamsters is the isolation of BIO53.58 from BIO14.6 [108]. Contrary to their forebears, BIO53.58 has a shorter life-expectancy and achieves much faster the disease endpoint of marked chamber dilation, which is common to all the CM hamsters, apparently without developing previous cardiac hypertrophy. Several descendants of BIO53.58, such as TO, TO-2 and MS200, were developed [180], and TO-2 is now maintained at Bio-Research Institute.

All the CM hamsters share the genomic deletion of about 30-kb interval, which includes the two promoters and first exons of delta-sarcoglycan gene with consequent loss of its protein product [212, 248, 249]. The consequences of the genetic loss of delta-sarcoglycan in heart are related not only to sarcolemmal fragility but also to coronary

vasospasm from disruption of dystrophin-associated protein complex [44]. A genetic insult yet to be discovered was probably introduced during the isolation of BIO53.58 and has been inherited by its descendants, which could explain its distinct cardiomyopathy.

Pathophysiologically, two basic mechanisms contribute to cardiomyopathy in this model: (1) ischemic heart disease by vasospasm of the coronary circulation and (2) cardiomyocyte loss due to intrinsic cell defects [66]. Reports suggested that the vascular RAAS plays a critical role in the generation of increased coronary reactivity and resistance in young Syrian CM hamsters that have not yet developed the clinical manifestations of HF, being the increased reactivity due to endothelial dysfunction secondary to angiotensin-II-dependent oxidative stress [66]. Indeed, blockade of the RAAS during early stages of disease improves the clinical manifestations of dilated cardiomyopathy in this model [66]. With regard to cardiomyocyte loss, numerous studies showed autophagic vacuolar degeneration in cardiomyocytes, which could be improved by treatment with granulocyte colony-stimulating factor [288]. Another report provided novel evidence of a beneficial effect of vascular endothelial growth factor in the Syrian CM hamster via induction of myogenic growth factor production by skeletal muscle and mobilization of progenitor cells, which resulted in attenuation of cardiomyopathy and repair of the heart [328].

Moreover, the Syrian CM hamster has been shown to develop alterations in electrical and ionic homeostasis related to disruption of gap junctions, which contributes to arrhythmogenesis during the development of HF [247]. A recent report showed that adhesion junction precedes gap junction alterations and that angiotensin-II receptor blockade might be a new therapy for lethal ventricular arrhythmia by modulating both adhesion junctions and gap junctions remodeling [323].

In summary, several reports confirm that CM hamsters with genetic loss of delta-sarcoglycan recapitulate many pathophysiologic aspects of cardiac failure [39, 267, 296], but it is clear that despite its extended use, this model is far from being totally understood [247].

Genetically engineered rodent models

The development of molecular biology offers the opportunity to study the impact of overexpression or deletion of specific genes involved in the pathophysiology of CHF. Indeed, transgenic murine models will help understanding the molecular basis of CHF, which might open the door for the development of novel molecular targets for the treatment of CHF. A wide number of genetic modifications have been successfully introduced in mice, either in terms

of gain or loss of function. Besides the genetically engineered mouse models summarized in Table 2, other selective inbred and other genetic animal models were presented in previous sections whenever appropriate.

General considerations

Besides ethical and philosophical questions, the use of animal models of HF needs careful consideration not only because the disease may be associated with discomfort and pain to the animal but also because results from animal studies are not readily transferable to human patients.

HF models were originally developed in rodents because of numerous potential advantages inherent to a small animal model. Housing and maintenance costs for rodents are much lower than for larger animals, thus allowing increasing the number of animals included in a given study and improving its statistical power. Moreover, recent technological advances in echocardiography, MRI and micromanometer conductance catheters have greatly upgraded the assessment of cardiac function in rodents, removing a significant barrier to their use in HF research.

The small size of mice presents some challenges in assessing myocardial function by conventional techniques (echocardiography, MRI), and the tenfold bigger myocardial mass of rats compared to mice gives the opportunity of performing more post-mortem histologic and biological analyses [223]. Nevertheless, cardiac physiologic assessments have been made easier by recent technologies such as ultrahigh resolution ultrasound [169] and micromanometer conductance for pressure–volume analyses [80, 218], but these techniques are quite expensive and pose a serious challenge to laboratories without an established expertise. The major advantage of mice compared to rats is the fact that pharmacologic studies become less expensive as the drug is usually administered proportionately to the animal weight. Moreover, mice are one of the most interesting research models to study the molecular basis of HF due to the availability of many genetically engineered strains made possible by their well-characterized genome and the easy introduction and stable transmission of gene mutations. Moreover, since 99% of the human genes have direct orthologs with mice, it is possible to generate transgenic mice models to mimic human disorders [71, 244]. Nevertheless, structural differences regarding human cardiovascular system represent another limitation of rodent models.

With regard to diastolic dysfunction, it should be emphasized that rodent models generally progress to SHF within a variable amount of time, which means in those animals DHF is only temporary step in the development of SHF. On the contrary, there are several human pathologies characterized by stable and isolated DHF, thus not evolving

to systolic dysfunction. Therefore, small animal models could be misleading because they suggest that DHF invariably progress to SHF, which in fact seldom happens in humans. Additionally, in humans, DHF is a condition typically associated with aging, and the diastolic dysfunction/DHF animal models herein mentioned are relatively young.

Care should be taken when dealing with genetically engineered mice. Besides taking into account strain and gender issues [91, 272, 283], high levels of overexpression must be carefully interpreted. In fact, transgenic mice that express a biologically inert green fluorescent protein in a cardiomyocyte-specific fashion develop LV hypertrophy, dilation and systolic dysfunction in a manner directly related to the level of protein expression. Therefore, non-specific effects on LV structure and function may result from vast overexpression of even biologically inactive proteins [112]. Furthermore, certain phenotypes depend on the expression level of the gene concerned [43, 298], which means it is necessary to develop multiple transgenic lines to establish a gene-dosage effect. Development of compensatory mechanisms could be triggered in response to gene overexpression or deletion at a very early stage after manipulation, masking the direct effects of the targeted gene. The use of inducible and conditional gene activation or deactivation could be a good way of overcoming this problem [306]. In conclusion, despite the inherent pitfalls in transgenesis, many of them can be circumvented by creating additional transgenic lines that can be used as controls to check dosage or epigenetic sequelae, as has been recently reviewed [202]. A number of difficulties in interpreting a cardiac transgenic experiment can arise from the promoter that drives the transgene itself. For example, although the α -myosin heavy chain (α -MHC) promoter is often thought of as driving ventricular expression in the adult, its actual expression pattern is considerably more nuanced, with transient expression in the embryonic heart tube and atrial expression throughout development. If the experimenter is attempting to isolate events that occur as a result of expression only in the adult, more precise manipulation of transgene expression may be necessary to generate interpretable data. Inducible transgene expression allows precise and reversible expression of a normal or mutated protein that can be directed to a particular cell type at a particular developmental time. A number of drug-inducible systems have been described, but the tetracycline-based system is the most effective and widely used. However, like most tools, it must be used carefully as the tetracycline activator can, when expressed at high levels or for long periods of time, be cardiotoxic. Despite this concern, transactivator lines have been developed that show no cardiotoxicity for at least 6 months, and so these experimental limitations can be easily circumvented [250].

Table 2 Brief description of the most important genetically engineered mouse models used for heart failure research

Gene	Mechanism	Structural changes	Functional changes	Comments
Cytoskeletal and sarcomeric proteins	Melusin [20]	Cardiac chamber dilation and relative wall thinning	Depressed systolic function and myocardial contractility, pulmonary congestion and impaired adrenal responsiveness	Melusin is a muscle-specific integrin $\beta 1$ -interacting protein. Probably required for LV hypertrophy induced by biochemical stress but not by humoral stimulation No effect on cardiac structure or basal function in physiologic conditions or in response to angiotensin II or phenylephrine Leads to LV hypertrophy and favors the transition toward dilated cardiomyopathy and contractile dysfunction in response to chronic pressure overload
	Muscle LIM protein (MLP) [7]	Myofiber disarray, severe LV hypertrophy, dilation and fibrosis	Systolic dysfunction and CHF Blunted response to β -agonist stimulation	Suitable model for long-term observation of drug effects on cardiac function and remodeling (near normal life span). Mutations in MLP were identified in patients with dilated or hypertrophic cardiomyopathy [199]
	Proteins linked to FHC (β -MHC, troponin T, MyBP-C) [176]	These models are important to study the mechanisms linking the primary mutation and the secondary development of CHF. Moreover, environmental or genetic factors play a role in the development of each phenotype		
	Proteins linked to heritable dilated cardiomyopathy (actin, β -MHC, troponin T) [267]	Severe disorganization of muscle architecture associated with degeneration [192] Reduced number of actin filaments and myofiber disarray	Early post-natal death [145]	Mutation in β -crystallin (a molecular chaperone heat shock protein essential for cytoskeletal integrity) causes a desmin-related myopathy [303]
	Cardiac actin Dystrophin		Dilated cardiomyopathy only in the presence of concomitant urotrophin deficiency [86]	

Table 2 continued

Gene		Mechanism	Structural changes	Functional changes	Comments
Neurohumoral receptors	$\alpha 1$ B-AR	Mutation	Ventricular hypertrophy increased ANF expression (sufficient for hypertrophy development)		Clinical studies with $\alpha 1$ -AR selective blockers or activators of central $\alpha 2$ -ARs have so far provided disappointing results [42]
	$\alpha 2$ A or $\alpha 2$ C-AR [25]	Knockout		Faster progression to CHF and death when challenged with pressure overload (TAC) than wild-type or $\alpha 2$ B knockout mice	The activation of subtype-specific $\alpha 2$ -AR at peripheral nerves has not been tried yet [306]
	$\beta 1$ -AR	Overexpression [63, 65]	Significant hypertrophy of the myocytes, altered nuclear morphology and concomitant fibrosis, with increased expression of apoptotic proteins in fibrotic areas	Elevated basal heart rate and increased contractility in young animals; at 35 weeks of age, the contractility decreases and many animals present clinical signs of HF and die before the age of 14 months. Contractile dysfunction is preceded by impaired Ca^{2+} handling [206]	Feedback presynaptic inhibition seems to be important to attenuate the detrimental effect of catecholamines
	$\beta 2$ -AR	Overexpression [264]	Myocardial hypertrophy that could not be prevented [57, 265, 266]	Basal contractility; LV dP/dtmax, relaxation and heart rate were increased [14, 17, 59, 190]. The improved contractility could be attributed to better Ca^{2+} cycling of the SR, which showed decreased PLN expression [242, 326]	Chronic activation clearly implicated in CHF development in both animal and clinical studies
	β -ARK1 [140]	Knockout	Mice do not survive	Other studies showed that mice die earlier from severe HF indicated by cardiac dilation, pulmonary congestion and pleural effusion [58, 159]	In a model with concomitant deletion of PLN gene, mice did not die prematurely anymore, the cardiac hypertrophy and fibrosis were inhibited, LV function was preserved and also the disturbed Ca^{2+} handling was restored
	β -ARK peptide inhibitor [140]	Overexpression			These findings show that the $\beta 1$ -adrenoceptor-PLB-signaling cascade is a crucial regulator of cardiac contractility [64, 172]
					In CHF, there is selective down-regulation of $\beta 1$ -AR and desensitization of both $\beta 1$ -AR and $\beta 2$ -AR (mediated by β -ARK1)
					Mice subjected to pressure overload through aortic constriction showed higher mortality and incidence of HF.
				Increased cardiac contractility	Cross-breeding with cardiomyopathic MLP-knockout mice restores the responsiveness to β -agonist stimulation and enhances cardiac contractility [238]
					Cross-breeding with mice overexpressing calsequestrin enhances cardiac function and reduces mortality. Combination with the β -blocker metoprolol has an additive effect [95]
					β -ARK1 seems to be a putative therapeutic target

Table 2 continued

Gene	Mechanism	Structural changes	Functional changes	Comments
Neurohumoral receptors	Renin-angiotensin system	AT-1 [221]	Overexpression	Significant cardiac hypertrophy and remodeling with increased expression of ANF and interstitial collagen deposition
Cytokines	TNF- α [143, 167]	Overexpression	Overexpression	Biventricular dilation, fibrosis, interstitial infiltrates and hypertrophy
	IL-6 and gp130 (receptor) [105, 106]	Overexpression	Disruption	Ventricular hypertrophy
	Gqz	Overexpression [47]	Overexpression	Myocardial apoptosis
Cellular signaling proteins	Heterotrimeric G proteins	Modest	Cardiac hypertrophy with increased expression of ANF and β -MHC	Gqz signaling is necessary and sufficient to the development of cardiac hypertrophy
		High	Cardiac hypertrophy	Mice with attenuated hypertrophic response to pressure overload (expression of Gqz peptide inhibitor or lack of norepinephrine) have increased wall stress but no decline in cardiac function [67]
		Transient expression of constitutively active Gqz [183]	Blunted response to β -agonist stimulation	Gq signaling pathway could be an interesting therapeutic target to prevent cardiac hypertrophy and CHF
		Inhibition (overexpression of a dominant-negative Gqz) [2, 312]	Overt CHF	
	Gzs	Modest overexpression [124]	Dilated cardiomyopathy	
	Gi	Conditional expression of Gi-coupled receptor (R_{01}) [233]	High level of expression causes hyperactive Gi signaling with systolic dysfunction	It is still matter of controversy if up-regulation of Gi pathway is a compensatory response to hyperactive G_s signaling
			Suppression of R_{01} expression after 8 weeks prevents further myocardial degeneration and partially improves systolic function and CHF	

Table 2 continued

Gene	Mechanism	Structural changes	Functional changes	Comments
Cellular signaling proteins	Small GTPases			
	Ras [114]	Hypertrophy	Diastolic dysfunction	
	RhoA [246]	Overexpression	Sinus and atrioventricular nodal dysfunction and contractile failure without ventricular hypertrophy	
	Rac1 [282]	Myocardial expression of a constitutively active form	Transient hypertrophy seen among juvenile mice that resolves with age	Lethal dilated cardiomyopathy associated with neonatal activation of the transgene
Protein kinases	PKC- β 2 [304]	Overexpression	Cardiac dilation and fibrosis	Reduced cardiac function
	PKC- α [201]	Knockout		Less systolic dysfunction and LV dilation in response to LAD
	PKC- ϵ [286]	Overexpression	Mild concentric hypertrophy without fibrosis	Normal cardiac function
	PKA [6]	Expression of catalytic subunit in heart		Dilated cardiomyopathy with arrhythmias and reduced cardiac function
	Calmodulin kinase II (CaMKII) [161]	Overexpression	Progressive LV hypertrophy and dilation	Overt CHF
	Calmodulin [90]	Overexpression	Myocardial hypertrophy	No CHF
	Calcineurin [201]	Overexpression	Myocardial hypertrophy	CHF development within 2 months
				CaMKII contributes to heart failure progression Expression of a cardiomyocyte-specific CaMKII inhibitory peptide reduces LV hypertrophy and dilation and systolic dysfunction [5]. A pharmacologic inhibitor of CaMKII (KN93) attenuated LV dilation and improved systolic function post-MI in wild-type rats, suggesting that this kinase could be a potential interesting therapeutic target [322] Other downstream pathways of calmodulin signaling could prevent the progression to CHF

Table 2 continued

Gene	Mechanism	Structural changes	Functional changes	Comments
Calcium-regulating proteins	Overexpression	Ventricular hypertrophy, apoptosis and fibrosis.	Overt CHF within 8 months and death of CHF within 12 months in the majority of mice	Restoration of β -AR signaling improves cardiac function and reduces mortality in these mice [95] SERCA2a overexpression improves systolic function and contractile reserve in mice with aortic constriction [123] Restoring adequate levels of SERCA2A expression in failing hearts improves LV systolic function, remodeling and survival [297] Mutation PLN9C identified in inherited human cardiomyopathy and the phenotype can be reproduced in mice [261] PLN inhibition could be a potential therapeutic target, but it is not certain if the beneficial effect would be the same in all types of CHF Ablation of PLN in G α_q overexpressing and mutant MyBP-C expressing mice does not correct global cardiac dysfunction Studies in animal models similar to most common forms of CHF in humans are needed
	Overexpression	Hypertrophy	Progressive CHF—increased SR Ca ²⁺ storage and decreased systolic Ca ²⁺ transients	
	Knockout [225]	Lethal in embryonic period	Impaired cardiac function	
	Heterozygous (null mutation) [225] Overexpression [9, 97] Overexpression		Enhanced cardiac relation and contractility	
S100A1 [229]	Overexpression		Increased adrenergic drive and mildly reduced ventricular contractility at the age of 3 months; overt CHF and death with aging [49]	S100A1 is a calcium regulatory protein that facilitates calcium transport across sarcoplasmic reticulum by optimizing activity of ryanodine receptor and SERCA2A A benzothiazepine derivative JTV519 prevents the decrease of RyR2-bound FKBP12.6, improves cardiac function and avoids cardiac remodeling in a canine model of CHF raising the question of it could be a novel therapeutic target [321]
	Knockout	Reverses cardiac remodeling and enhances cardiac function in mice overexpressing calsequestrin [252]	Increased contractility [170] Preserves cardiac contractility and left ventricular chamber size close to normal in MLP-deficient mice [193] Restoring expression of S100A1 to normal levels in post-MI rats improved LV function and reduced LV dilation	
	Overexpression		Restoring expression of S100A1 to normal levels in post-MI rats improved LV function and reduced LV dilation	
	Knockout	Cardiac hypertrophy	Disregulation of Ca ²⁺ release in the myocytes	
RyR [317]	Knockout	Cardiac hypertrophy	Disregulation of Ca ²⁺ release in the myocytes	

Table 2 continued

Gene	Mechanism	Structural changes	Functional changes	Comments
ECM proteins				
$\beta 1$ -integrin [269]	Knockout (cardiac selective)	Myocardial fibrosis	CHF	
MMP-2 [96]	Knockout	Decreased LV dilation and rupture	Better cardiac function and survival rate in mice subjected to LAD ligation.	
MMP-9 [61]	Knockout	Reduced LV dilation and collagen accumulation following LAD occlusion.		
TIMP-1 [45]	Knockout	Increased LV remodeling after MI		
Oxidative stress	Tissue-specific conditional knockout	Dilated cardiomyopathy with fibrosis at 4 months of age	Reduced contractility	Molecular defects in mitochondrial respiration suggested that administration of antioxidants could restore cardiac contractility
AR adrenergic receptor, ANF atrial natriuretic factor, PLN phospholamban, SR sarcoplasmic reticulum, AT-1 angiotensin receptor 1, β -MHC β -myosin heavy chain, MyBP-C myosin binding protein-C, PKA protein kinase A, PKC protein kinase C, RyR ryanodine receptor, ECM extracellular matrix, MMP matrix metalloproteinase, TIMP tissue inhibitor of metalloproteinase, Mn-SOD manganese superoxide dismutase				

Gene targeting has often been heralded as being more precise and useful than transgenesis. When coupled with tissue- or cell type-specific methodologies via Cre-lox technology, gene targeting offers a precise way of introducing specific mutations that will only be expressed in a defined cell type at a particular developmental time. Nonetheless, the continuous expression of the Cre recombinase system has been shown to cause decreased growth, cytopathic effects and chromosomal aberrations in cultured cells lacking exogenous lox sites [260, 275]. A self-excising retroviral vector that incorporates a negative feedback loop to limit the duration and intensity of Cre expression can avoid measurable toxicity, while retaining the ability to excise a target sequence flanked by lox sites, thus providing the basis of a less toxic strategy for the use of Cre or similar recombinases [275]. As is the case for transgenesis, the more precisely the targeting event can be manipulated, the more straightforward the data interpretation will be. In the heart, this is accomplished by rendering the targeting event cardiomyocyte specific via controlled Cre expression using a cardiomyocyte-specific promoter or even making cardiomyocyte-specific Cre expression inducible [277]. However, several reports have noted some cardiac toxicity due to high levels of Cre expression with the α -MHC promoter, especially in later adulthood [202]. One putative solution is to design the experiment such that the data are obtained before cardiac function and biochemistry are affected, circumventing any negative effect of Cre expression. More importantly, employing Cre-only transgenic mice in the same genetic background as part of the overall experimental design is absolutely necessary for proper data interpretation and to ascertain any potential effect of Cre alone. Alternatively, different cardiac Cre transgenes may be used. Moreover, tamoxifen administration only in the presence of the α -MHC-MerCreMer transgene produces a temporary reduction in cardiac function with some ventricular dilation, although this phenotype resolves in 7–14 days after tamoxifen administration [202]. Thus, if the MerCreMer transgene is used to inducibly delete a gene from the heart, controls that only contain this transgene with tamoxifen are critical.

Another drawback of rodent models is that many protocols have a sudden onset of HF due to a surgical or drug intervention, whereas human HF generally develops over a period of several years. Most models also use young adult animals, while human patients are usually old. In addition, human HF is often associated with atherosclerosis, hypertension, diabetes or obesity, but the development of atherosclerosis is rather rare in most rodent strains [92].

In addition, even though rodent models have been extremely useful in developing concepts concerning the pathogenesis of heart failure, apart from the Pfeffer's model [228], which predicted the utility of ACE inhibitors

in post-infarction [227], they have not predicted outcomes in phase III clinical trials. Although translation of findings to clinical trials requires preclinical studies where the appropriate animal model is used for either acute or chronic HF, therapeutic results obtained in small animal models are not necessarily predictive of outcomes in human patients but can provide a potential future approach in the human context. In this regard, two recent examples could be mentioned. Inhibitors of enzymes in the PDE5 family have been used to raise cGMP content in cardiac muscle in animal models of pressure overload, chronic β -adrenergic receptor stimulation, ischemic injury and doxorubicin toxicity showing antihypertrophic and cardioprotective actions. However, recent experimental results raise some question regarding the applicability of these findings to humans, in whose hearts PDE5 is present at much lower levels than those seen in animal models, and raise the possibility of PDE1, a dual-specificity phosphodiesterase present at high levels in human myocardium, as an alternative target for inotropic and cardioprotective actions [205]. On the other hand, despite the evidence for inflammatory activation as an important pathway in disease progression in chronic HF and the promising results of 'anti-inflammatory' therapies (such as antitumor necrosis factor- α approaches) in rodent models [146], clinical trials have hitherto failed to show benefit in HF patients [101]. The discrepancy between clinical and basic research findings could be explained by the inherent physiologic differences between humans and rodents in terms of pharmacokinetics and pharmacogenetics. On the other hand, several authors reinforce the importance of refining patient selection in order to optimize the benefits of new HF drugs [101, 174].

Finally, the majority of the numerous genetic studies performed in mice have not resulted in clinically approved treatment in humans thus far [202]. However, it is not uncommon for a drug to take over 20 years from inception to clinical application. Given that genetically modified mouse models have only recently become a mainstay approach, it may take many more years before approaches based on this technology are introduced into clinical practice.

Conclusion

The use of small animal models has proven to be an extremely valuable tool in understanding the pathophysiology of complex cardiovascular diseases like CHF. Due to the recent development of invasive and non-invasive techniques to evaluate hemodynamics in human patients, animal models of HF are becoming less important to study hemodynamics, neurohumoral activation and myocardial

function. Furthermore, with cardiac transplantation surgery, end-stage human myocardium become available for molecular and biochemical studies. Nevertheless, animal models remain critically important to study myocardial changes during compensated, initial stages of CHF, during transition from hypertrophy to failure and during the process of remodeling, all of which are currently difficult or even impossible to follow serially in human patients. Animal models may also be relevant to study the effects of new pharmacologic interventions on hemodynamics, neurohumoral activation and survival under preclinical conditions.

At present, transgenic models of CHF are essential for understanding the molecular alterations underlying the development of the disease, as they allow the identification of genes that are causative for HF and to characterize molecular mechanisms responsible for the development and progression of the disease.

Finally, animal models that mimic distinct features of human HF will play an important role in unraveling the consequences of gene transfer and molecular techniques to correct disturbed subcellular processes in the failing heart. These experiments are indispensable, and these rodent models will continue to hold an important role, not only in expanding our knowledge about the mechanisms underlying HF, but also in developing novel therapeutic strategies for CHF.

Acknowledgments This work was supported by a grant from the European Commission (FP7-Health-2010; MEDIA-261409). Inês Falcão-Pires, Ana Luisa Pires and Carmen Brás-Silva are supported by an individual grants from Portuguese Foundation for Science and Technology (SFRH/BPD/66176/2009, SFRH/BD/19544/2004 as well as Ciência 2008 and PTDC/SAU-FCT/100442/2008, COMPETE, FEDER, respectively).

References

1. Abbate A, Scarpa S, Santini D, Palheiro J, Vasaturo F, Miller J, Morales C, Vetrovec GW, Baldi A (2006) Myocardial expression of survivin, an apoptosis inhibitor, in aging and heart failure. An experimental study in the spontaneously hypertensive rat. *Int J Cardiol* 111:371–376. doi:[10.1016/j.ijcard.2005.07.061](https://doi.org/10.1016/j.ijcard.2005.07.061)
2. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ (1998) Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. *Science* 280:574–577
3. Akhter SA, Milano CA, Shotwell KF, Cho MC, Rockman HA, Lefkowitz RJ, Koch WJ (1997) Transgenic mice with cardiac overexpression of α 1B-adrenergic receptors. In vivo α 1-adrenergic receptor-mediated regulation of beta-adrenergic signaling. *J Biol Chem* 272:21253–21259
4. An D, Rodrigues B (2006) Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. *Am J Physiol Heart Circ Physiol* 291:H1489–1506. doi:[10.1152/ajpheart.00278.2006](https://doi.org/10.1152/ajpheart.00278.2006)

5. Anderson ME (2005) Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. *Pharmacol Ther* 106:39–55. doi:[10.1016/j.pharmthera.2004.11.002](https://doi.org/10.1016/j.pharmthera.2004.11.002)
6. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA, Marks AR, Olson EN (2001) Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase α . *Circ Res* 89:997–1004
7. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P (1997) MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. *Cell* 88:393–403
8. Arnolda L, McGrath B, Cocks M, Sumithran E, Johnston C (1985) Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms. *Cardiovasc Res* 19:378–382
9. Baker DL, Hashimoto K, Grupp IL, Ji Y, Reed T, Loukianov E, Grupp G, Bhagwat A, Hoit B, Walsh R, Marban E, Periasamy M (1998) Targeted overexpression of the sarcoplasmic reticulum Ca^{2+} -ATPase increases cardiac contractility in transgenic mouse hearts. *Circ Res* 83:1205–1214
10. Bayat H, Swaney JS, Ander AN, Dalton N, Kennedy BP, Hammond HK, Roth DM (2002) Progressive heart failure after myocardial infarction in mice. *Basic Res Cardiol* 97:206–213
11. Berg RG, Leenen FH, de Jong W (1979) Plasma renin activity and sodium, potassium and water excretion during reversal of hypertension in the one-clip two-kidney hypertensive rat. *Clin Sci (Lond)* 57:47–52
12. Bialik GM, Abassi ZA, Hammel I, Winaver J, Lewinson D (2001) Evaluation of atrial natriuretic peptide and brain natriuretic peptide in atrial granules of rats with experimental congestive heart failure. *J Histochem Cytochem* 49:1293–1300
13. Bing OH, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, Sen S, Conrad CH (1995) The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. *J Mol Cell Cardiol* 27:383–396
14. Bittner HB, Chen EP, Milano CA, Lefkowitz RJ, Van Trigt P (1997) Functional analysis of myocardial performance in murine hearts overexpressing the human β_2 -adrenergic receptor. *J Mol Cell Cardiol* 29:961–967. doi:[10.1006/jmcc.1996.0339](https://doi.org/10.1006/jmcc.1996.0339)
15. Boluyt MO, O'Neill L, Meredith AL, Bing OH, Brooks WW, Conrad CH, Crow MT, Lakatta EG (1994) Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. *Circ Res* 75:23–32
16. Boluyt MO, Robinson KG, Meredith AL, Sen S, Lakatta EG, Crow MT, Brooks WW, Conrad CH, Bing OH (2005) Heart failure after long-term supravalvular aortic constriction in rats. *Am J Hypertens* 18:202–212. doi:[10.1016/j.amjhyper.2004.08.034](https://doi.org/10.1016/j.amjhyper.2004.08.034)
17. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF et al (1995) Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β_2 -adrenoceptor. *Nature* 374:272–276. doi:[10.1038/374272a0](https://doi.org/10.1038/374272a0)
18. Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. *Circulation* 115:3213–3223. doi:[10.1161/CIRCULATIONAHA.106.679597](https://doi.org/10.1161/CIRCULATIONAHA.106.679597)
19. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG, Abel ED (2007) Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. *Diabetes* 56:2457–2466. doi:[10.2337/db07-0481](https://doi.org/10.2337/db07-0481)
20. Brancaccio M, Fratta L, Notte A, Hirsch E, Poulet R, Guazzone S, De Acetis M, Vecchione C, Marino G, Altruda F, Silengo L, Tarone G, Lembo G (2003) Melusin, a muscle-specific integrin β 1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. *Nat Med* 9:68–75. doi:[10.1038/nm805nm805](https://doi.org/10.1038/nm805nm805)
21. Bras-Silva C, Fontes-Sousa AP, Moura C, Areias JC, Leite-Moreira AF (2006) Impaired response to ET(B) receptor stimulation in heart failure: functional evidence of endothelial dysfunction? *Exp Biol Med (Maywood)* 231:893–898
22. Bras-Silva C, Leite-Moreira AF (2008) Myocardial effects of endothelin-1. *Rev Port Cardiol* 27:925–951
23. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD, Schrenzel M, Krieger M (2002) Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. *Circ Res* 90:270–276
24. Braunschweig F, Cowie MR, Auricchio A (2011) What are the costs of heart failure? *Europace* 13(Suppl 2):ii13–17. doi:[10.1093/europace/eur081](https://doi.org/10.1093/europace/eur081)
25. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, Lohse MJ, Hein L (2002) Feedback inhibition of catecholamine release by two different α_2 -adrenoceptor subtypes prevents progression of heart failure. *Circulation* 106:2491–2496
26. Brenner DA, Apstein CS, Saupe KW (2001) Exercise training attenuates age-associated diastolic dysfunction in rats. *Circulation* 104:221–226
27. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC (1978) Early anthracycline cardiotoxicity. *Am J Med* 65:823–832
28. Brower GL, Levick SP, Janicki JS (2007) Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. *Am J Physiol Heart Circ Physiol* 292:H3057–3064. doi:[10.1152/ajpheart.00447.2006](https://doi.org/10.1152/ajpheart.00447.2006)
29. Brown L, Ooi SY, Lau K, Sernia C (2000) Cardiac and vascular responses in deoxycorticosterone acetate-salt hypertensive rats. *Clin Exp Pharmacol Physiol* 27:263–269
30. Buermans HP, Redout EM, Schiel AE, Musters RJ, Zuidwijk M, Eijk PP, van Hardeveld C, Kasanmoentalib S, Visser FC, Ylstra B, Simonides WS (2005) Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure. *Physiol Genomics* 21:314–323. doi:[10.1152/physiolgenomics.00185.2004](https://doi.org/10.1152/physiolgenomics.00185.2004)
31. Bugger H, Abel ED (2008) Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. *Clin Sci (Lond)* 114:195–210. doi:[10.1042/CS20070166](https://doi.org/10.1042/CS20070166)
32. Burke SL, Evans RG, Head GA (2011) Effects of chronic sympatho-inhibition on renal excretory function in renovascular hypertension. *J Hypertens* 29:945–952. doi:[10.1097/HJH.0b013e3283449529](https://doi.org/10.1097/HJH.0b013e3283449529)
33. Calderone A, de Champlain J, Rouleau JL (1991) Adriamycin-induced changes to the myocardial β -adrenergic system in the rabbit. *J Mol Cell Cardiol* 23:333–342
34. Cantor EJ, Babick AP, Vasanji Z, Dhalla NS, Neticadan T (2005) A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overload. *J Mol Cell Cardiol* 38:777–786. doi:[10.1016/j.yjmcc.2005.02.012](https://doi.org/10.1016/j.yjmcc.2005.02.012)
35. Carvalho KA, Guarita-Souza LC, Hansen P, Rebelatto CL, Senegaglia AC, Miyague N, Olandoski M, Francisco JC,

- Furuta M, Gremski W (2006) Cell transplantation after the coculture of skeletal myoblasts and mesenchymal stem cells in the regeneration of the myocardium scar: an experimental study in rats. *Transplant Proc* 38:1596–1602. doi:[10.1016/j.transproceed.2006.03.023](https://doi.org/10.1016/j.transproceed.2006.03.023)
36. Cavallero S, Gonzalez GE, Puyo AM, Roson MI, Perez S, Morales C, Hertig CM, Gelpi RJ, Fernandez BE (2007) Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volume-induced cardiac hypertrophy. *J Hypertens* 25:1940–1950. doi:[10.1097/HJH.0b013e3282435b1e00004872-200709000-00026](https://doi.org/10.1097/HJH.0b013e3282435b1e00004872-200709000-00026)
 37. Chekanov VS (1999) A stable model of chronic bilateral ventricular insufficiency (dilated cardiomyopathy) induced by arteriovenous anastomosis and doxorubicin administration in sheep. *J Thorac Cardiovasc Surg* 117:198–199
 38. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP (1996) Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. *Cell* 84:491–495
 39. Chen J, Chien KR (1999) Complexity in simplicity: monogenic disorders and complex cardiomyopathies. *J Clin Invest* 103:1483–1485. doi:[10.1172/JCI7297](https://doi.org/10.1172/JCI7297)
 40. Chen Y, Daosukho C, Opii WO, Turner DM, Pierce WM, Klein JB, Vore M, Butterfield DA, St Clair DK (2006) Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice. *Free Radic Biol Med* 41:1470–1477. doi:[10.1016/j.freeradbiomed.2006.08.006](https://doi.org/10.1016/j.freeradbiomed.2006.08.006)
 41. Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL (1996) Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. *Science* 271:994–996
 42. Cohn JN (2002) Sympathetic nervous system in heart failure. *Circulation* 106:2417–2418
 43. Colbert MC, Hall DG, Kimball TR, Witt SA, Lorenz JN, Kirby ML, Hewett TE, Klevitsky R, Robbins J (1997) Cardiac compartment-specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice. *J Clin Invest* 100:1958–1968. doi:[10.1172/JCI119727](https://doi.org/10.1172/JCI119727)
 44. Coral-Vazquez R, Cohn RD, Moore SA, Hill JA, Weiss RM, Davisson RL, Straub V, Barresi R, Bansal D, Hrstka RF, Williamson R, Campbell KP (1999) Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. *Cell* 98:465–474
 45. Creemers EE, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, Hauet AM, Escobar PG, Cleutjens JP, Smits JF, Daemen MJ, Zile MR, Spinale FG (2003) Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. *Am J Physiol Heart Circ Physiol* 284:H364–371. doi:[10.1152/ajpheart.00511.2002](https://doi.org/10.1152/ajpheart.00511.2002)
 46. Cunha-Neto E, Dzau VJ, Allen PD, Stamatiou D, Benvenuti L, Higuchi ML, Koyama NS, Silva JS, Kalil J, Liew CC (2005) Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. *Am J Pathol* 167:305–313. doi:[10.1016/S0002-9440\(10\)62976-8](https://doi.org/10.1016/S0002-9440(10)62976-8)
 47. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn GW 2nd (1997) Transgenic Galphaq overexpression induces cardiac contractile failure in mice. *Proc Natl Acad Sci USA* 94:8121–8126
 48. Dahl LK, Heine M, Tassinari L (1962) Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. *Nature* 194:480–482
 49. Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW 2nd, Kranias EG (2001) Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. *Circulation* 103:889–896
 50. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anversa P (2010) Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. *Circulation* 121:276–292. doi:[10.1161/CIRCULATIONAHA.109.895771](https://doi.org/10.1161/CIRCULATIONAHA.109.895771)
 51. Delgado RM 3rd, Nawar MA, Zewail AM, Kar B, Vaughn WK, Wu KK, Aleksic N, Sivasubramanian N, McKay K, Mann DL, Willerson JT (2004) Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. *Circulation* 109:1428–1433. doi:[10.1161/01.CIR.0000121354.34067.48](https://doi.org/10.1161/01.CIR.0000121354.34067.48)
 52. Devi S, Kennedy RH, Joseph L, Shekhawat NS, Melchert RB, Joseph J (2006) Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. *Cardiovasc Pathol* 15:75–82. doi:[10.1016/j.carpath.2005.11.001](https://doi.org/10.1016/j.carpath.2005.11.001)
 53. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur J Heart Fail* 10:933–989. doi:[10.1016/j.ejheart.2008.08.005](https://doi.org/10.1016/j.ejheart.2008.08.005)
 54. Dodd DA, Atkinson JB, Olson RD, Buck S, Cusack BJ, Fleischer S, Boucek RJ Jr (1993) Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. *J Clin Invest* 91:1697–1705. doi:[10.1172/JCI116379](https://doi.org/10.1172/JCI116379)
 55. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, Ono K, Kuzuya T, Hirota S, Koyama T, Miwa T, Hori M (2000) Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. *J Hypertens* 18:111–120
 56. Drolet MC, Lachance D, Plante E, Roussel E, Couet J, Arsenault M (2006) Gender-related differences in left ventricular remodeling in chronic severe aortic valve regurgitation in rats. *J Heart Valve Dis* 15:345–351
 57. Du XJ, Autelitano DJ, Dilley RJ, Wang B, Dart AM, Woodcock EA (2000) beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. *Circulation* 101:71–77
 58. Du XJ, Gao XM, Wang B, Jennings GL, Woodcock EA, Dart AM (2000) Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing beta(2)-adrenergic receptors in the heart. *Cardiovasc Res* 48:448–454
 59. Du XJ, Vincan E, Woodcock DM, Milano CA, Dart AM, Woodcock EA (1996) Response to cardiac sympathetic activation in transgenic mice overexpressing beta 2-adrenergic receptor. *Am J Physiol* 271:H630–H636
 60. Dubi S, Arbel Y (2010) Large animal models for diastolic dysfunction and diastolic heart failure—a review of the literature. *Cardiovasc Pathol* 19:147–152. doi:[10.1016/j.carpath.2008.12.008](https://doi.org/10.1016/j.carpath.2008.12.008)
 61. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT (2000)

- Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. *J Clin Invest* 106:55–62. doi:[10.1172/JCI8768](https://doi.org/10.1172/JCI8768)
62. El-Demerdash E, Awad AS, Taha RM, El-Hady AM, Sayed-Ahmed MM (2005) Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat. *Pharmacol Res* 51:311–318. doi:[10.1016/j.phrs.2004.10.002](https://doi.org/10.1016/j.phrs.2004.10.002)
 63. Engelhardt S, Boknik P, Keller U, Neumann J, Lohse MJ, Hein L (2001) Early impairment of calcium handling and altered expression of junctin in hearts of mice overexpressing the beta1-adrenergic receptor. *FASEB J* 15:2718–2720. doi:[10.1096/fj.01-0107fje](https://doi.org/10.1096/fj.01-0107fje)
 64. Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ (2004) Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. *Circulation* 109:1154–1160. doi:[10.1161/01.CIR.0000117254.68497.39](https://doi.org/10.1161/01.CIR.0000117254.68497.39)
 65. Engelhardt S, Hein L, Wiesmann F, Lohse MJ (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. *Proc Natl Acad Sci USA* 96:7059–7064
 66. Escobales N, Crespo MJ (2008) Early pathophysiological alterations in experimental cardiomyopathy: the Syrian cardiomyopathic hamster. *P R Health Sci J* 27:307–314
 67. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. *Circulation* 105:85–92
 68. Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR (2001) From infection to autoimmunity. *J Autoimmun* 16:175–186. doi:[10.1006/jaut.2000.0492](https://doi.org/10.1006/jaut.2000.0492)
 69. Falcao-Pires I, Palladini G, Goncalves N, van der Velden J, Moreira-Goncalves D, Miranda-Silva D, Salinaro F, Paulus WJ, Niessen HW, Perlini S, Leite-Moreira AF (2011) Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. *Basic Res Cardiol* 106:801–814. doi:[10.1007/s00395-011-0184-x](https://doi.org/10.1007/s00395-011-0184-x)
 70. Feldman AM, Weinberg EO, Ray PE, Lorell BH (1993) Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. *Circ Res* 73:184–192
 71. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. *J Clin Invest* 109:121–130. doi:[10.1172/JCI14080](https://doi.org/10.1172/JCI14080)
 72. Francis GS, Tang WH (2003) Pathophysiology of congestive heart failure. *Rev Cardiovasc Med* 4(Suppl 2):S14–S20
 73. Freeman RH, Davis JO, Watkins BE, Stephens GA, DeForrest JM (1979) Effects of continuous converting enzyme blockade on renovascular hypertension in the rat. *Am J Physiol* 236:F21–F24
 74. Fu M, Matoba M, Liang QM, Sjogren KG, Hjalmarson A (1994) Properties of G-protein modulated receptor-adenylyl cyclase system in myocardium of spontaneously hypertensive rats treated with adriamycin. *Int J Cardiol* 44:9–18
 75. Fujihira S, Yamamoto T, Matsumoto M, Yoshizawa K, Oishi Y, Fujii T, Noguchi H, Mori H (1993) The high incidence of atrial thrombosis in mice given doxorubicin. *Toxicol Pathol* 21:362–368
 76. Gao XM, Dart AM, Dewar E, Jennings G, Du XJ (2000) Serial echocardiographic assessment of left ventricular dimensions and function after myocardial infarction in mice. *Cardiovasc Res* 45:330–338
 77. Garcia R, Diebold S (1990) Simple, rapid, and effective method of producing aortocaval shunts in the rat. *Cardiovasc Res* 24:430–432
 78. Gaudin PB, Hruban RH, Beschoner WE, Kasper EK, Olson JL, Baughman KL, Hutchins GM (1993) Myocarditis associated with doxorubicin cardiotoxicity. *Am J Clin Pathol* 100:158–163
 79. Gehrmann J, Frantz S, Maguire CT, Vargas M, Ducharme A, Wakimoto H, Lee RT, Berul CI (2001) Electrophysiological characterization of murine myocardial ischemia and infarction. *Basic Res Cardiol* 96:237–250
 80. Georgakopoulos D, Mitzner WA, Chen CH, Byrne BJ, Millar HD, Hare JM, Kass DA (1998) In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. *Am J Physiol* 274:H1416–H1422
 81. Goldblatt H, Lynch J, Hanzal RF, Summerville WW (1934) Studies on Experimental Hypertension : I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. *J Exp Med* 59:347–379
 82. Gomez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, Cannell MB, McCune SA, Altschuld RA, Lederer WJ (1997) Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. *Science* 276:800–806
 83. Goser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Ottl R, Zittlich S, Blaudeck N, Hardt SE, Pfitzer G, Rose NR, Katus HA, Kaya Z (2006) Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. *Circulation* 114:1693–1702. doi:[10.1161/CIRCULATIONAHA.106.635664](https://doi.org/10.1161/CIRCULATIONAHA.106.635664)
 84. Goto Y, Suzuki K, Ono T, Sasaki M, Toyota T (1988) Development of diabetes in the non-obese NIDDM rat (GK rat). *Adv Exp Med Biol* 246:29–31
 85. Gould KE, Taffet GE, Michael LH, Christie RM, Konkol DL, Pocius JS, Zachariah JP, Chaupin DF, Daniel SL, Sandusky GE Jr, Hartley CJ, Entman ML (2002) Heart failure and greater infarct expansion in middle-aged mice: a relevant model for postinfarction failure. *Am J Physiol Heart Circ Physiol* 282:H615–H621. doi:[10.1152/ajpheart.00206.2001](https://doi.org/10.1152/ajpheart.00206.2001)
 86. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR (1997) Skeletal and cardiac myopathies in mice lacking dystrophin and dystrophin: a model for Duchenne muscular dystrophy. *Cell* 90:729–738
 87. Greer JJ, Ware DP, Lefer DJ (2006) Myocardial infarction and heart failure in the db/db diabetic mouse. *Am J Physiol Heart Circ Physiol* 290:H146–153. doi:[10.1152/ajpheart.00583.2005](https://doi.org/10.1152/ajpheart.00583.2005)
 88. Grimm D, Elsner D, Schunkert H, Pfeifer M, Griesse D, Bruckschlegel G, Muders F, Riegger GA, Kromer EP (1998) Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. *Cardiovasc Res* 37:91–100
 89. Grobe JL, Mecca AP, Mao H, Katovich MJ (2006) Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension. *Am J Physiol Heart Circ Physiol* 290:H2417–2423. doi:[10.1152/ajpheart.01170.2005](https://doi.org/10.1152/ajpheart.01170.2005)
 90. Gruver CL, DeMayo F, Goldstein MA, Means AR (1993) Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. *Endocrinology* 133:376–388
 91. Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester JW, Zhai J, Kimura Y, Dorn GW 2nd, MacLennan DH, Kranias EG (2001) Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. *J Biol Chem* 276:24145–24152. doi:[10.1074/jbc.M102403200](https://doi.org/10.1074/jbc.M102403200)
 92. Halapas A, Papalois A, Stauropoulou A, Philippou A, Pissimissis N, Chatzigeorgiou A, Kamper E, Koutsilieris M (2008) In vivo models for heart failure research. *In Vivo* 22:767–780
 93. Halapas A, Pissimissis N, Lembessis P, Rizos I, Rigopoulos AG, Kremastinos DT, Koutsilieris M (2008) Molecular diagnosis of the viral component in cardiomyopathies: pathophysiological,

- clinical and therapeutic implications. *Expert Opin Ther Targets* 12:821–836. doi:[10.1517/14728222.12.7.821](https://doi.org/10.1517/14728222.12.7.821)
94. Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, Sasayama S, Matsumori A (2002) Evidence for a role of mast cells in the evolution to congestive heart failure. *J Exp Med* 195:375–381
 95. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA (2001) Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. *Proc Natl Acad Sci USA* 98:5809–5814. doi:[10.1073/pnas.091102398](https://doi.org/10.1073/pnas.091102398)
 96. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A (2003) Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. *Am J Physiol Heart Circ Physiol* 285:H1229–1235. doi:[10.1152/ajpheart.00207.2003](https://doi.org/10.1152/ajpheart.00207.2003)
 97. He H, Giordano FJ, Hilal-Dandan R, Choi DJ, Rockman HA, McDonough PM, Bluhm WF, Meyer M, Sayen MR, Swanson E, Dillmann WH (1997) Overexpression of the rat sarcoplasmic reticulum Ca^{2+} -ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. *J Clin Invest* 100:380–389. doi:[10.1172/JCI119544](https://doi.org/10.1172/JCI119544)
 98. Herman EH, Ferrans VJ (1998) Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. *Semin Oncol* 25:15–21
 99. Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A (2006) Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. *Am J Physiol Heart Circ Physiol* 291:H2424–2430. doi:[10.1152/ajpheart.00369.2006](https://doi.org/10.1152/ajpheart.00369.2006)
 100. Heyen JR, Blasi ER, Nikula K, Rocha R, Daust HA, Friedrich G, Van Vleet JF, De Ciechi P, McMahon EG, Rudolph AE (2002) Structural, functional, and molecular characterization of the SHHF model of heart failure. *Am J Physiol Heart Circ Physiol* 283:H1775–H1784. doi:[10.1152/ajpheart.00305.2002](https://doi.org/10.1152/ajpheart.00305.2002)
 101. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss HP, Tschope C, Van Bilsen M, Zannad F, McMurray J, Shah AM (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 11:119–129. doi:[10.1093/eurjhf/hfn043](https://doi.org/10.1093/eurjhf/hfn043)
 102. Heymans S, Pauschinger M, De Palma A, Kallwellis-Opapa A, Rutschow S, Swinnen M, Vanhoutte D, Gao F, Torpai R, Baker AH, Padalko E, Neyts J, Schultheiss HP, Van de Werf F, Carmeliet P, Pinto YM (2006) Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. *Circulation* 114:565–573. doi:[10.1161/CIRCULATIONAHA.105.591032](https://doi.org/10.1161/CIRCULATIONAHA.105.591032)
 103. Hibbs RG, Ferrans VJ, Walsh JJ, Burch GE (1965) Electron microscopic observations on lysosomes and related cytoplasmic components of normal and pathological cardiac muscle. *Anat Rec* 153:173–185
 104. Hirono S, Islam MO, Nakazawa M, Yoshida Y, Kodama M, Shibata A, Izumi T, Imai S (1997) Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics. *Circ Res* 80:11–20
 105. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, Muller W, Chien KR (1999) Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. *Cell* 97:189–198
 106. Hirota H, Yoshida K, Kishimoto T, Taga T (1995) Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. *Proc Natl Acad Sci USA* 92:4862–4866
 107. Holycross BJ, Summers BM, Dunn RB, McCune SA (1997) Plasma renin activity in heart failure-prone SHHF/Mcc-facp rats. *Am J Physiol* 273:H228–H233
 108. Homburger F (1979) Myopathy of hamster dystrophy: history and morphologic aspects. *Ann N Y Acad Sci* 317:1–17
 109. Homburger F, Baker JR, Nixon CW, Wilgram G (1962) New hereditary disease of Syrian hamsters. Primary, generalized polymyopathy and cardiac necrosis. *Arch Intern Med* 110:660–662
 110. Homburger F, Nixon CW, Eppenberger M, Baker JR (1966) Hereditary myopathy in the Syrian hamster: studies on pathogenesis. *Ann N Y Acad Sci* 138:14–27
 111. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE (2003) Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. *Am J Physiol Heart Circ Physiol* 285:H1261–1269. doi:[10.1152/ajpheart.00108.2003](https://doi.org/10.1152/ajpheart.00108.2003)
 112. Huang WY, Aramburu J, Douglas PS, Izumo S (2000) Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. *Nat Med* 6:482–483. doi:[10.1038/74914](https://doi.org/10.1038/74914)
 113. Hunter EG, Hughes V, White J (1984) Cardiomyopathic hamsters, CHF 146 and CHF 147: a preliminary study. *Can J Physiol Pharmacol* 62:1423–1428
 114. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR (1995) Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. *J Biol Chem* 270:23173–23178
 115. Hwang GS, Oh KS, Koo HN, Seo HW, You KH, Lee BH (2006) Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure. *Eur J Pharmacol* 540:131–138. doi:[10.1016/j.ejphar.2006.04.031](https://doi.org/10.1016/j.ejphar.2006.04.031)
 116. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T, Yokota M (2006) Attenuation of cardiac dysfunction by a PPAR- α agonist is associated with down-regulation of redox-regulated transcription factors. *J Mol Cell Cardiol* 41:318–329. doi:[10.1016/j.jymcc.2006.05.013](https://doi.org/10.1016/j.jymcc.2006.05.013)
 117. Ikegami T, Suzuki Y, Shimizu T, Isono K, Koseki H, Shirasawa T (2002) Model mice for tissue-specific deletion of the manganese superoxide dismutase (MnSOD) gene. *Biochem Biophys Res Commun* 296:729–736
 118. Ingalls AM, Dickie MM, Snell GD (1950) Obese, a new mutation in the house mouse. *J Hered* 41:317–318
 119. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S (1994) Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. *Am J Physiol* 267:H2471–H2482
 120. Intengan HD, Park JB, Schiffrin EL (1999) Blood pressure and small arteries in DOCA-salt-treated genetically AVP-deficient rats: role of endothelin. *Hypertension* 34:907–913
 121. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK (1994) Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. *J Clin Invest* 93:1885–1893. doi:[10.1172/JCI117179](https://doi.org/10.1172/JCI117179)
 122. Ito H, Torii M, Suzuki T (1995) Decreased superoxide dismutase activity and increased superoxide anion production in cardiac hypertrophy of spontaneously hypertensive rats. *Clin Exp Hypertens* 17:803–816
 123. Ito K, Yan X, Feng X, Manning WJ, Dillmann WH, Lorell BH (2001) Transgenic expression of sarcoplasmic reticulum Ca^{2+} -ATPase modifies the transition from hypertrophy to early heart failure. *Circ Res* 89:422–429

124. Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP, Kudej RK, Wight DC, Wagner TE, Ishikawa Y, Homcy CJ, Vatner SF (1996) Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. *Circ Res* 78:517–524
125. Janssen SW, Martens GJ, Sweep CG, Ross HA, Hermus AR (1999) In Zucker diabetic fatty rats plasma leptin levels are correlated with plasma insulin levels rather than with body weight. *Horm Metab Res* 31:610–615. doi:[10.1055/s-2007-978806](https://doi.org/10.1055/s-2007-978806)
126. Jasmin G, Eu HY (1979) Cardiomyopathy of hamster dystrophy. *Ann N Y Acad Sci* 317:46–58
127. Jeong D, Cha H, Kim E, Kang M, Yang DK, Kim JM, Yoon PO, Oh JG, Bernecker OY, Sakata S, Le TT, Cui L, Lee YH, Kim do H, Woo SH, Liao R, Hajjar RJ, Park WJ (2006) PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. *Circ Res* 99:307–314. doi:[10.1161/01.RES.0000234780.06115.2c](https://doi.org/10.1161/01.RES.0000234780.06115.2c)
128. Jones LR, Suzuki YJ, Wang W, Kobayashi YM, Ramesh V, Franzini-Armstrong C, Cleemann L, Morad M (1998) Regulation of Ca²⁺ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. *J Clin Invest* 101:1385–1393. doi:[10.1172/JCI1362](https://doi.org/10.1172/JCI1362)
129. Joseph J, Joseph L, Shekhawat NS, Devi S, Wang J, Melchert RB, Hauer-Jensen M, Kennedy RH (2003) Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. *Am J Physiol Heart Circ Physiol* 285:H679–686. doi:[10.1152/ajpheart.00145.2003](https://doi.org/10.1152/ajpheart.00145.2003)
130. Joseph J, Washington A, Joseph L, Koehler L, Fink LM, Hauer-Jensen M, Kennedy RH (2002) Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. *Am J Physiol Heart Circ Physiol* 283:H2567–2574. doi:[10.1152/ajpheart.00475.2002](https://doi.org/10.1152/ajpheart.00475.2002)
131. Junhong W, Jing Y, Jizheng M, Shushu Z, Xiangjian C, Hengfang W, Di Y, Jinan Z (2008) Proteomic analysis of left ventricular diastolic dysfunction hearts in renovascular hypertensive rats. *Int J Cardiol* 127:198–207. doi:[10.1016/j.ijcard.2007.07.003](https://doi.org/10.1016/j.ijcard.2007.07.003)
132. Katholi RE, Naftilan AJ, Oparil S (1980) Importance of renal sympathetic tone in the development of DOCA-salt hypertension in the rat. *Hypertension* 2:266–273
133. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications—Otsuka Long-Evans Tokushima Fatty (OleTf) strain. *Diabetes* 41:1422–1428
134. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R, Hoshino K, Takewa Y, Sakata S, Peluso R, Zsebo K, Gwathmey JK, Tardif JC, Tanguay JF, Hajjar RJ (2008) Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. *J Am Coll Cardiol* 51:1112–1119. doi:[10.1016/j.jacc.2007.12.014](https://doi.org/10.1016/j.jacc.2007.12.014)
135. Kay JM, Smith P, Heath D (1969) Electron microscopy of Crotalaria pulmonary hypertension. *Thorax* 24:511–526
136. Kazumi T, Odaka H, Hozumi T, Ishida Y, Amano N, Yoshino G (1997) Effects of dietary fructose or glucose on triglyceride production and lipogenic enzyme activities in the liver of Wistar fatty rats, an animal model of NIDDM. *Endocr J* 44:239–245
137. Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, Iwao H (2001) Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. *Circulation* 103:148–154
138. Kiss E, Ball NA, Kranias EG, Walsh RA (1995) Differential changes in cardiac phospholamban and sarcoplasmic reticular Ca(2⁺)-ATPase protein levels. Effects on Ca²⁺ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. *Circ Res* 77:759–764
139. Klotz S, Hay I, Zhang G, Maurer M, Wang J, Burkhoff D (2006) Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. *Hypertension* 47:901–911. doi:[10.1161/01.HYP.0000215579.81408.8e](https://doi.org/10.1161/01.HYP.0000215579.81408.8e)
140. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, Lefkowitz RJ (1995) Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. *Science* 268:1350–1353
141. Konduracka E, Gackowski A, Rostoff P, Galicka-Latala D, Frasiak W, Piwowarska W (2007) Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. *Eur Heart J* 28:2465–2471. doi:[10.1093/eurheartj/ehm361](https://doi.org/10.1093/eurheartj/ehm361)
142. Krzeminski TF, Nozynski JK, Grzyb J, Porc M (2008) Widespread myocardial remodeling after acute myocardial infarction in rat. Features for heart failure progression. *Vascu Pharmacol* 48:100–108. doi:[10.1016/j.vph.2008.01.002](https://doi.org/10.1016/j.vph.2008.01.002)
143. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. *Circ Res* 81:627–635
144. Kuhlmann MT, Kirchhof P, Klocke R, Hasib L, Stypmann J, Fabritz L, Stelljes M, Tian W, Zwiener M, Mueller M, Kienast J, Breithardt G, Nikol S (2006) G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. *J Exp Med* 203:87–97. doi:[10.1084/jem.20051151](https://doi.org/10.1084/jem.20051151)
145. Kumar A, Crawford K, Close L, Madison M, Lorenz J, Doetschman T, Pawlowski S, Duffy J, Neumann J, Robbins J, Boivin GP, O'Toole BA, Lessard JL (1997) Rescue of cardiac alpha-actin-deficient mice by enteric smooth muscle gamma-actin. *Proc Natl Acad Sci USA* 94:4406–4411
146. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N, Entman ML, Mann DL (2000) Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. *Proc Natl Acad Sci U S A* 97:5456–5461. doi:[10.1073/pnas.070036297](https://doi.org/10.1073/pnas.070036297)
147. Kuwajima I, Kardon MB, Pegram BL, Sesoko S, Frohlich ED (1982) Regression of left ventricular hypertrophy in two-kidney, one clip Goldblatt hypertension. *Hypertension* 4:113–118
148. Langenickel T, Pagel I, Hohnel K, Dietz R, Willenbrock R (2000) Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. *Am J Physiol Heart Circ Physiol* 278:H1500–H1506
149. Lebrecht D, Kokkari A, Ketelsen UP, Setzer B, Walker UA (2005) Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. *J Pathol* 207:436–444. doi:[10.1002/path.1863](https://doi.org/10.1002/path.1863)
150. Leenen FH, de Jong W (1975) Plasma renin and sodium balance during development of moderate and severe renal hypertension in rats. *Circ Res* 36:179–186
151. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer* 32:302–314
152. Leite-Moreira AF (2006) Current perspectives in diastolic dysfunction and diastolic heart failure. *Heart* 92:712–718. doi:[10.1136/hrt.2005.062950](https://doi.org/10.1136/hrt.2005.062950)
153. Li JM, Yao ZF, Zou YZ, Ge JB, Guan AL, Wu J, Mi SL, Liang YY, Ma Z (2011) The therapeutic potential of G-CSF in pressure overload induced ventricular reconstruction and heart failure in mice. *Mol Biol Rep* doi:[10.1007/s11033-011-0703-8](https://doi.org/10.1007/s11033-011-0703-8)
154. Li L, Chu Y, Fink GD, Engelhardt JF, Heistad DD, Chen AF (2003) Endothelin-1 stimulates arterial VCAM-1 expression via

- NADPH oxidase-derived superoxide in mineralocorticoid hypertension. *Hypertension* 42:997–1003. doi:[10.1161/01.HYP.0000095980.43859.59](https://doi.org/10.1161/01.HYP.0000095980.43859.59)
155. Li Y, Takemura G, Kosai K, Takahashi T, Okada H, Miyata S, Yuge K, Nagano S, Esaki M, Khai NC, Goto K, Mikami A, Maruyama R, Minatoguchi S, Fujiwara T, Fujiwara H (2004) Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. *Circ Res* 95:627–636. doi:[10.1161/01.RES.0000141528.54850.bd](https://doi.org/10.1161/01.RES.0000141528.54850.bd)
 156. Li YY, Feldman AM (2001) Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. *Drugs* 61:1239–1252
 157. Li Z, Bing OH, Long X, Robinson KG, Lakatta EG (1997) Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. *Am J Physiol* 272:H2313–H2319
 158. Li Z, Tran TT, Ma JY, O'Young G, Kapoun AM, Chakravarty S, Dugar S, Schreiner G, Protter AA (2004) p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats. *J Cardiovasc Pharmacol* 44:486–492.
 159. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, Dorn GW 2nd (2000) Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. *Circulation* 101:1707–1714
 160. Lim CC, Zuppingner C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, Sawyer DB (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. *J Biol Chem* 279:8290–8299. doi:[10.1074/jbc.M308033200](https://doi.org/10.1074/jbc.M308033200)
 161. Ling H, Zhang T, Pereira L, Means CK, Cheng H, Gu Y, Dalton ND, Peterson KL, Chen J, Bers D, Heller Brown J (2009) Requirement for Ca²⁺/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. *J Clin Invest* 119:1230–1240. doi:[10.1172/JCI38022](https://doi.org/10.1172/JCI38022)
 162. Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigemma GP, Douglas PS (1995) Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. *Circulation* 91:2642–2654
 163. Liu P, Penninger J, Aitken K, Sole M, Mak T (1995) The role of transgenic knockout models in defining the pathogenesis of viral heart disease. *Eur Heart J* 16 Suppl O:25–27
 164. Liu YH, Yang XP, Nass O, Sabbah HN, Peterson E, Carretero OA (1997) Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. *Am J Physiol* 272:H722–H727
 165. Liu Z, Hilbelink DR, Crockett WB, Gerdes AM (1991) Regional changes in hemodynamics and cardiac myocyte size in rats with aortocaval fistulas. 1. Developing and established hypertrophy. *Circ Res* 69:52–58
 166. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J (2010) Heart disease and stroke statistics—2010 update: a report from the American Heart Association. *Circulation* 121:e46–e215. doi:[10.1161/CIRCULATIONAHA.109.192667](https://doi.org/10.1161/CIRCULATIONAHA.109.192667)
 167. London B, Baker LC, Lee JS, Shusterman V, Choi BR, Kubota T, McTiernan CF, Feldman AM, Salama G (2003) Calcium-dependent arrhythmias in transgenic mice with heart failure. *Am J Physiol Heart Circ Physiol* 284:H431–441. doi:[10.1152/ajpheart.00431.2002](https://doi.org/10.1152/ajpheart.00431.2002)
 168. Lou H, Danelisen I, Singal PK (2004) Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. *J Mol Cell Cardiol* 36:683–690. doi:[10.1016/j.yjmcc.2004.03.004](https://doi.org/10.1016/j.yjmcc.2004.03.004)
 169. Luo J, Fujikura K, Homma S, Konofagou EE (2007) Myocardial elastography at both high temporal and spatial resolution for the detection of infarcts. *Ultrasound Med Biol* 33:1206–1223. doi:[10.1016/j.ultrasmedbio.2007.01.019](https://doi.org/10.1016/j.ultrasmedbio.2007.01.019)
 170. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, Kranias EG (1994) Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. *Circ Res* 75:401–409
 171. Lygate CA, Schneider JE, Hulbert K, ten Hove M, Sebag-Montefiore LM, Cassidy PJ, Clarke K, Neubauer S (2006) Serial high resolution 3D-MRI after aortic banding in mice: band internalization is a source of variability in the hypertrophic response. *Basic Res Cardiol* 101:8–16. doi:[10.1007/s00395-005-0546-3](https://doi.org/10.1007/s00395-005-0546-3)
 172. MacLennan DH, Kranias EG (2003) Phospholamban: a crucial regulator of cardiac contractility. *Nat Rev Mol Cell Biol* 4:566–577. doi:[10.1038/nrm1151](https://doi.org/10.1038/nrm1151)
 173. Maier LS, Wahl-Schott C, Horn W, Weichert S, Pagel C, Wagner S, Dybkova N, Muller OJ, Nabauer M, Franz WM, Pieske B (2005) Increased SR Ca²⁺ cycling contributes to improved contractile performance in SERCA2a-overexpressing transgenic rats. *Cardiovasc Res* 67:636–646. doi:[10.1016/j.cardiores.2005.05.006](https://doi.org/10.1016/j.cardiores.2005.05.006)
 174. Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. *Circ Res* 91:988–998
 175. Manning RD Jr, Meng S, Tian N (2003) Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. *Acta Physiol Scand* 179:243–250
 176. Marian AJ, Roberts R (2001) The molecular genetic basis for hypertrophic cardiomyopathy. *J Mol Cell Cardiol* 33:655–670. doi:[10.1006/jmcc.2001.1340](https://doi.org/10.1006/jmcc.2001.1340)
 177. Matsumori A, Kawai C (1982) An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. *Circulation* 65:1230–1235
 178. Matsumori A, Sasayama S (1995) Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy—lessons from animal experiments. *Eur Heart J* 16 Suppl O:140–143
 179. Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, Ogenorth TJ, Takaoka M (1999) Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. *Hypertension* 33:759–765
 180. McCully JD, Jandreski MA, Liew J, Sole MJ, Liew CC (1987) Construction of cosmid genomic libraries for the normal and myopathic Syrian hamsters. *Biochem Cell Biol* 65:997–1000
 181. McMurray J, Pfeffer MA (2002) New therapeutic options in congestive heart failure: Part I. *Circulation* 105:2099–2106
 182. McMurray J, Pfeffer MA (2002) New therapeutic options in congestive heart failure: Part II. *Circulation* 105:2223–2228
 183. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ (1998) Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. *Proc Natl Acad Sci USA* 95:13893–13898
 184. Mendez GF, Cowie MR (2001) The epidemiological features of heart failure in developing countries: a review of the literature. *Int J Cardiol* 80:213–219

185. Menna P, Recalcati S, Cairo G, Minotti G (2007) An introduction to the metabolic determinants of anthracycline cardiotoxicity. *Cardiovasc Toxicol* 7:80–85. doi:[10.1007/s12012-007-0011-7](https://doi.org/10.1007/s12012-007-0011-7)
186. Mering JV MO (1889) Diabetes mellitus nach Pankreasextirpation. *Centralblatt für klinische Medizin*, Leipzig 10:383
187. Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM (1995) Myocardial ischemia and reperfusion: a murine model. *Am J Physiol* 269: H2147–H2154
188. Michael O'Donnell J, Narayan P, Bailey MQ, Abduljalil AM, Altschuld RA, McCune SA, Robitaille PM (1998) ³¹P-NMR analysis of congestive heart failure in the SHHF/Mcc-facp rat heart. *J Mol Cell Cardiol* 30:235–241. doi:[10.1006/jmcc.1997.0587](https://doi.org/10.1006/jmcc.1997.0587)
189. Mihm MJ, Yu F, Weinstein DM, Reiser PJ, Bauer JA (2002) Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. *Br J Pharmacol* 135:581–588. doi:[10.1038/sj.bjp.0704495](https://doi.org/10.1038/sj.bjp.0704495)
190. Milano CA, Allen LF, Dolber PC, Johnson TD, Rockman HA, Bond RA, Lefkowitz RJ (1995) Marked enhancement in myocardial function resulting from overexpression of a human beta-adrenergic receptor gene. *J Thorac Cardiovasc Surg* 109:236–241
191. Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, Lefkowitz RJ (1994) Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. *Proc Natl Acad Sci USA* 91:10109–10113
192. Milner DJ, Weitzer G, Tran D, Bradley A, Capetanaki Y (1996) Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. *J Cell Biol* 134:1255–1270
193. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR (1999) Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. *Cell* 99:313–322
194. Mitchell GF, Pfeffer JM, Pfeffer MA (1997) The transition to failure in the spontaneously hypertensive rat. *Am J Hypertens* 10:120S–126S
195. Moens AL, Champion HC, Claeys MJ, Tavazzi B, Kaminski PM, Wolin MS, Borgonjon DJ, Van Nassauw L, Haile A, Zviman M, Bedja D, Wuyts FL, Elsaesser RS, Cos P, Gabrielson KL, Lazzarino G, Paolocci N, Timmermans JP, Vrints CJ, Kass DA (2008) High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. *Circulation* 117:1810–1819. doi:[10.1161/CIRCULATIONAHA.107.725481](https://doi.org/10.1161/CIRCULATIONAHA.107.725481)
196. Moens AL, Ketner EA, Takimoto E, Schmidt TS, O'Neill CA, Wolin MS, Alp NJ, Channon KM, Kass DA (2011) Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure. *J Mol Cell Cardiol*. doi:[10.1016/j.yjmcc.2011.05.017](https://doi.org/10.1016/j.yjmcc.2011.05.017)
197. Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, Arkenbout EK, Champion HC, Bedja D, Gabrielson KL, Chen J, Xia Y, Hale AB, Channon KM, Halushka MK, Barker N, Wuyts FL, Kaminski PM, Wolin MS, Kass DA, Barouch LA (2009) Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. *J Mol Cell Cardiol* 47:576–585. doi:[10.1016/j.yjmcc.2009.06.005](https://doi.org/10.1016/j.yjmcc.2009.06.005)
198. Mohammed SF, Storie JR, Oehler EA, Bowen LA, Korinek J, Lam CS, Simari RD, Burnett JC Jr, Redfield MM (2011) Variable phenotype in murine transverse aortic constriction. *Cardiovasc Pathol*. doi:[10.1016/j.carpath.2011.05.002](https://doi.org/10.1016/j.carpath.2011.05.002)
199. Mohapatra B, Jimenez S, Lin JH, Bowles KR, Coveler KJ, Marx JG, Chrisco MA, Murphy RT, Lurie PR, Schwartz RJ, Elliott PM, Vatta M, McKenna W, Towbin JA, Bowles NE (2003) Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. *Mol Genet Metab* 80:207–215
200. Molina EJ, Gupta D, Palma J, Torres D, Gaughan JP, Houser S, Macha M (2009) Novel experimental model of pressure overload hypertrophy in rats. *J Surg Res* 153:287–294. doi:[10.1016/j.jss.2008.03.043](https://doi.org/10.1016/j.jss.2008.03.043)
201. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. *Cell* 93:215–228
202. Molkentin JD, Robbins J (2009) With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure. *J Mol Cell Cardiol* 46:130–136. doi:[10.1016/j.yjmcc.2008.09.002](https://doi.org/10.1016/j.yjmcc.2008.09.002)
203. Monnet E, Chachques JC (2005) Animal models of heart failure: what is new? *Ann Thorac Surg* 79:1445–1453. doi:[10.1016/j.athoracsur.2004.04.002](https://doi.org/10.1016/j.athoracsur.2004.04.002)
204. Moreau P, Schiffrin EL (2003) Role of endothelins in animal models of hypertension: focus on cardiovascular protection. *Can J Physiol Pharmacol* 81:511–521. doi:[10.1139/y03-015](https://doi.org/10.1139/y03-015)
205. Movsesian MA, Kukreja RC (2011) Phosphodiesterase inhibition in heart failure. *Handb Exp Pharmacol* 237–249 doi:[10.1007/978-3-642-17969-3_10](https://doi.org/10.1007/978-3-642-17969-3_10)
206. Muller FU, Kirchhefer U, Begrow F, Reinke U, Neumann J, Schmitz W (2002) Junctional sarcoplasmic reticulum transmembrane proteins in the heart. *Basic Res Cardiol* 97(Suppl 1): I52–I55
207. Murakami K, Mizushige K, Noma T, Tsuji T, Kimura S, Kohno M (2002) Perindopril effect on uncoupling protein and energy metabolism in failing rat hearts. *Hypertension* 40:251–255
208. Murata T, Yamawaki H, Yoshimoto R, Hori M, Sato K, Ozaki H, Karki H (2001) Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study. *Life Sci* 69:2685–2695
209. Muth JN, Bodi I, Lewis W, Varadi G, Schwartz A (2001) A Ca(2+)-dependent transgenic model of cardiac hypertrophy: a role for protein kinase Calpha. *Circulation* 103:140–147
210. Nagano M, Kato M, Nagai M, Yang J (1991) Protective effect of ACE- and kininase-inhibitor on the onset of cardiomyopathy. *Basic Res Cardiol* 86(Suppl 3):187–195
211. Nagatsu M, Zile MR, Tsutsui H, Schmid PG, DeFreyte G, Cooper GT, Carabello BA (1994) Native beta-adrenergic support for left ventricular dysfunction in experimental mitral regurgitation normalizes indexes of pump and contractile function. *Circulation* 89:818–826
212. Nigro V, Okazaki Y, Belsito A, Piluso G, Matsuda Y, Politano L, Nigro G, Ventura C, Abbondanza C, Molinari AM, Acampora D, Nishimura M, Hayashizaki Y, Puca GA (1997) Identification of the Syrian hamster cardiomyopathy gene. *Hum Mol Genet* 6:601–607
213. Nishio R, Sasayama S, Matsumori A (2002) Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis. *J Am Coll Cardiol* 40:1506–1514
214. O'Donnell SM, Hansberger MW, Connolly JL, Chappell JD, Watson MJ, Pierce JM, Wetzel JD, Han W, Barton ES, Forrest JC, Valyi-Nagy T, Yull FE, Blackwell TS, Rottman JN, Sherry B, Dermody TS (2005) Organ-specific roles for transcription factor NF-kappaB in reovirus-induced apoptosis and disease. *J Clin Invest* 115:2341–2350. doi:[10.1172/JCI22428](https://doi.org/10.1172/JCI22428)
215. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I (2004) Myocardial fibrosis and diastolic

- dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor- α activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor- κ B pathway. *J Am Coll Cardiol* 43:1481–1488. doi:[10.1016/j.jacc.2003.11.043](https://doi.org/10.1016/j.jacc.2003.11.043)
216. Oudit GY, Crackower MA, Eriksson U, Sarao R, Kozieradzki I, Sasaki T, Irie-Sasaki J, Gidrewicz D, Rybin VO, Wada T, Steinberg SF, Backx PH, Penninger JM (2003) Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. *Circulation* 108:2147–2152. doi:[10.1161/01.CIR.0000091403.62293.2B](https://doi.org/10.1161/01.CIR.0000091403.62293.2B)
 217. Ozek C, Zhang F, Lineaweaver WC, Chin BT, Eiman T, Newlin L, Buncke HJ (1998) A new heart failure model in rat by an end-to-side femoral vessel anastomosis. *Cardiovasc Res* 37:236–238
 218. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA (2008) Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. *Nat Protoc* 3:1422–1434. doi:[10.1038/nprot.2008.138](https://doi.org/10.1038/nprot.2008.138)
 219. Padmanabhan M, Prince PS (2006) Preventive effect of S-allylcysteine on lipid peroxides and antioxidants in normal and isoproterenol-induced cardiotoxicity in rats: a histopathological study. *Toxicology* 224:128–137. doi:[10.1016/j.tox.2006.04.039](https://doi.org/10.1016/j.tox.2006.04.039)
 220. Padmanabhan M, Rajadurai M, Prince PS (2008) Preventive effect of S-allylcysteine on membrane-bound enzymes and glycoproteins in normal and isoproterenol-induced cardiac toxicity in male Wistar rats. *Basic Clin Pharmacol Toxicol* 103:507–513. doi:[10.1111/j.1742-7843.2008.00244.x](https://doi.org/10.1111/j.1742-7843.2008.00244.x)
 221. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M (2000) Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. *Proc Natl Acad Sci USA* 97:931–936
 222. Park SC, Liu-Stratton Y, Medeiros LC, McCune SA, Radin MJ (2004) Effect of male sex and obesity on platelet arachidonic acid in spontaneous hypertensive heart failure rats. *Exp Biol Med (Maywood)* 229:657–664
 223. Patten RD, Hall-Porter MR (2009) Small animal models of heart failure: development of novel therapies, past and present. *Circ Heart Fail* 2:138–144. doi:[10.1161/CIRCHEARTFAILURE.108.839761](https://doi.org/10.1161/CIRCHEARTFAILURE.108.839761)
 224. Peng X, Chen B, Lim CC, Sawyer DB (2005) The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. *Mol Interv* 5:163–171. doi:[10.1124/mi.5.3.6](https://doi.org/10.1124/mi.5.3.6)
 225. Periasamy M, Reed TD, Liu LH, Ji Y, Loukianov E, Paul RJ, Nieman ML, Riddle T, Duffy JJ, Doetschman T, Lorenz JN, Shull GE (1999) Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca²⁺-ATPase isoform 2 (SERCA2) gene. *J Biol Chem* 274:2556–2562
 226. Pfeffer JM, Pfeffer MA, Fishbein MC, Frohlich ED (1979) Cardiac function and morphology with aging in the spontaneously hypertensive rat. *Am J Physiol* 237:H461–H468
 227. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E (1982) Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. *Proc Natl Acad Sci USA* 79:3310–3314
 228. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E (1979) Myocardial infarct size and ventricular function in rats. *Circ Res* 44:503–512
 229. Plegier ST, Remppis A, Heidt B, Volkers M, Chuprun JK, Kuhn M, Zhou RH, Gao E, Szabo G, Weichenhan D, Muller OJ, Eckhart AD, Katus HA, Koch WJ, Most P (2005) S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. *Mol Ther* 12:1120–1129. doi:[10.1016/j.ymthe.2005.08.002](https://doi.org/10.1016/j.ymthe.2005.08.002)
 230. Plestina R, Stoner HB (1972) Pulmonary oedema in rats given monocrotaline pyrrole. *J Pathol* 106:235–249. doi:[10.1002/path.1711060405](https://doi.org/10.1002/path.1711060405)
 231. Porter CB, Walsh RA, Badke FR, O'Rourke RA (1983) Differential effects of diltiazem and nitroprusside on left ventricular function in experimental chronic volume overload. *Circulation* 68:685–692
 232. Rakieten N, Rakieten ML, Nadkarni MV (1963) Studies on the diabetogenic action of streptozotocin (NSC-37917). *Cancer Chemother Rep* 29:91–98
 233. Redfern CH, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, Nanevich T, Fidelman N, Desai K, Vranizan K, Lee EK, Coward P, Shah N, Warrington JA, Fishman GI, Bernstein D, Baker AJ, Conklin BR (2000) Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. *Proc Natl Acad Sci USA* 97:4826–4831
 234. Redfield MM (2000) Epidemiology and pathophysiology of heart failure. *Curr Cardiol Rep* 2:179–180
 235. Reed AL, Tanaka A, Sorescu D, Liu H, Jeong EM, Sturdy M, Walp ER, Dudley SC Jr, Sutliff RL (2011) Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. *Am J Physiol Heart Circ Physiol* 301:H824–831. doi:[10.1152/ajpheart.00407.2010](https://doi.org/10.1152/ajpheart.00407.2010)
 236. Rerup CC (1970) Drugs producing diabetes through damage of the insulin secreting cells. *Pharmacol Rev* 22:485–518
 237. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R Jr, Rossi MA, Tanus-Santos JE, Gerlach RF (2010) Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. *J Card Fail* 16:599–608. doi:[10.1016/j.cardfail.2010.02.005](https://doi.org/10.1016/j.cardfail.2010.02.005)
 238. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J Jr, Lefkowitz RJ, Koch WJ (1998) Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. *Proc Natl Acad Sci USA* 95:7000–7005
 239. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhilber ME, Field LJ, Ross J Jr, Chien KR (1991) Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. *Proc Natl Acad Sci USA* 88:8277–8281
 240. Rockman HA, Wachhorst SP, Mao L, Ross J Jr (1994) ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. *Am J Physiol* 266:H2468–H2475
 241. Rodriguez-Iturbe B, Quiroz Y, Kim CH, Vaziri ND (2005) Hypertension induced by aortic coarctation above the renal arteries is associated with immune cell infiltration of the kidneys. *Am J Hypertens* 18:1449–1456. doi:[10.1016/j.amjhyper.2005.05.034](https://doi.org/10.1016/j.amjhyper.2005.05.034)
 242. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK (1999) Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. *J Biol Chem* 274:16701–16708
 243. Ruiz-Hurtado G, Fernandez-Velasco M, Mourelle M, Delgado C (2007) LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. *Hypertension* 50:1049–1056. doi:[10.1161/HYPERTENSIONAHA.107.093666](https://doi.org/10.1161/HYPERTENSIONAHA.107.093666)
 244. Ruiz P, Witt H (2006) Microarray analysis to evaluate different animal models for human heart failure. *J Mol Cell Cardiol* 40:13–15. doi:[10.1016/j.yjmcc.2005.09.010](https://doi.org/10.1016/j.yjmcc.2005.09.010)
 245. Ryu JH, Kim IK, Cho SW, Cho MC, Hwang KK, Piao H, Piao S, Lim SH, Hong YS, Choi CY, Yoo KJ, Kim BS (2005) Implantation of bone marrow mononuclear cells using injectable fibrin matrix enhances neovascularization in infarcted myocardium.

- Biomaterials 26:319–326. doi:[10.1016/j.biomaterials.2004.02.058](https://doi.org/10.1016/j.biomaterials.2004.02.058)
246. Sah VP, Minamisawa S, Tam SP, Wu TH, Dorn GW 2nd, Ross J Jr, Chien KR, Brown JH (1999) Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. *J Clin Invest* 103:1627–1634. doi:[10.1172/JCI6842](https://doi.org/10.1172/JCI6842)
 247. Sakamoto A (2004) Electrical and ionic abnormalities in the heart of cardiomyopathic hamsters: in quest of a new paradigm for cardiac failure and lethal arrhythmia. *Mol Cell Biochem* 259:183–187
 248. Sakamoto A, Abe M, Masaki T (1999) Delineation of genomic deletion in cardiomyopathic hamster. *FEBS Lett* 447:124–128
 249. Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, Masaki T, Toyo-oka T, Hanaoka F (1997) Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. *Proc Natl Acad Sci USA* 94:13873–13878
 250. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J (2003) Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. *Circ Res* 92:609–616. doi:[10.1161/01.RES.0000065442.64694.9F](https://doi.org/10.1161/01.RES.0000065442.64694.9F)
 251. Sato Y, Ferguson DG, Sako H, Dorn GW 2nd, Kadambi VJ, Yatani A, Hoit BD, Walsh RA, Kranias EG (1998) Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. *J Biol Chem* 273:28470–28477
 252. Sato Y, Kiriazis H, Yatani A, Schmidt AG, Hahn H, Ferguson DG, Sako H, Mitarai S, Honda R, Mesnard-Rouiller L, Frank KF, Beyermann B, Wu G, Fujimori K, Dorn GW 2nd, Kranias EG (2001) Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. *J Biol Chem* 276:9392–9399. doi:[10.1074/jbc.M006889200](https://doi.org/10.1074/jbc.M006889200)
 253. Satoh S, Ueda Y, Suematsu N, Oyama J, Kadokami T, Sugano M, Yoshikawa Y, Makino N (2003) Beneficial effects of angiotensin-converting enzyme inhibition on sarcoplasmic reticulum function in the failing heart of the Dahl rat. *Circ J* 67:705–711
 254. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA (1999) Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. *Circ Res* 84:257–265
 255. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? *Prog Cardiovasc Dis* 53:105–113. doi:[10.1016/j.pcad.2010.06.007](https://doi.org/10.1016/j.pcad.2010.06.007)
 256. Scheuermann-Freestone M, Freestone NS, Langenickel T, Hohnel K, Dietz R, Willenbrock R (2001) A new model of congestive heart failure in the mouse due to chronic volume overload. *Eur J Heart Fail* 3:535–543
 257. Schiffrin EL (2000) Endothelin: role in experimental hypertension. *J Cardiovasc Pharmacol* 35:S33–S35
 258. Schiffrin EL (2001) Role of endothelin-1 in hypertension and vascular disease. *Am J Hypertens* 14:83S–89S. doi:[S089570610102074X](https://doi.org/10.1016/j.pcad.2010.06.007)
 259. Schlenker EH, Kost CK Jr, Likness MM (2004) Effects of long-term captopril and L-arginine treatment on ventilation and blood pressure in obese male SHHF rats. *J Appl Physiol* 97:1032–1039. doi:[10.1152/jappphysiol.00255.2004](https://doi.org/10.1152/jappphysiol.00255.2004)
 260. Schmidt-Supprian M, Rajewsky K (2007) Vagaries of conditional gene targeting. *Nat Immunol* 8:665–668. doi:[10.1038/ni0707-665](https://doi.org/10.1038/ni0707-665)
 261. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman JG, Seidman CE (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. *Science* 299:1410–1413. doi:[10.1126/science.1081578299/5611/1410](https://doi.org/10.1126/science.1081578299/5611/1410)
 262. Schoental R, Head MA (1955) Pathological changes in rats as a result of treatment with monocrotaline. *Br J Cancer* 9:229–237
 263. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH (1990) Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. *J Clin Invest* 86:1913–1920. doi:[10.1172/JCI114924](https://doi.org/10.1172/JCI114924)
 264. Schwarz B, Percy E, Gao XM, Dart AM, Richardt G, Du XJ (2003) Altered calcium transient and development of hypertrophy in beta2-adrenoceptor overexpressing mice with and without pressure overload. *Eur J Heart Fail* 5:131–136
 265. Schwinger RH, Bohm M, Erdmann E (1990) Evidence against spare or uncoupled beta-adrenoceptors in the human heart. *Am Heart J* 119:899–904
 266. Schwinger RH, Bohm M, Schmidt U, Karczewski P, Bavendiek U, Flesch M, Krause EG, Erdmann E (1995) Unchanged protein levels of SERCA II and phospholamban but reduced Ca²⁺ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. *Circulation* 92:3220–3228
 267. Seidman JG, Seidman C (2001) The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. *Cell* 104:557–567
 268. Selye H (1942) Production of nephrosclerosis by overdosage with desoxycorticosterone acetate. *Can Med Assoc J* 47:515–519
 269. Shai SY, Harpf AE, Babbitt CJ, Jordan MC, Fishbein MC, Chen J, Omura M, Leil TA, Becker KD, Jiang M, Smith DJ, Cherry SR, Loftus JC, Ross RS (2002) Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. *Circ Res* 90:458–464
 270. Shen FM, Xie HH, Ling G, Xu LP, Su DF (2005) Synergistic effects of atenolol and amlodipine for lowering and stabilizing blood pressure in 2K1C renovascular hypertensive rats. *Acta Pharmacol Sin* 26:1303–1308. doi:[10.1111/j.1745-7254.2005.00185.x](https://doi.org/10.1111/j.1745-7254.2005.00185.x)
 271. Shimizu T, Nojiri H, Kawakami S, Uchiyama S, Shirasawa T (2010) Model mice for tissue-specific deletion of the manganese superoxide dismutase gene. *Geriatr Gerontol Int* 10(Suppl 1):S70–79. doi:[10.1111/j.1447-0594.2010.00604.x](https://doi.org/10.1111/j.1447-0594.2010.00604.x)
 272. Shusterman V, Usiene I, Harrigal C, Lee JS, Kubota T, Feldman AM, London B (2002) Strain-specific patterns of autonomic nervous system activity and heart failure susceptibility in mice. *Am J Physiol Heart Circ Physiol* 282:H2076–H2083. doi:[10.1152/ajpheart.00917.2001](https://doi.org/10.1152/ajpheart.00917.2001)
 273. Sicard P, Oudot A, Guillaud JC, Moreau D, Vergely C, Rochette L (2006) Dissociation between vascular oxidative stress and cardiovascular function in Wistar Kyoto and spontaneously hypertensive rats. *Vascul Pharmacol* 45:112–121. doi:[10.1016/j.vph.2006.04.001](https://doi.org/10.1016/j.vph.2006.04.001)
 274. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, Boulden BM, Widder J, Fredd S, Bernstein KE, Wolska BM, Dikalov S, Harrison DG, Dudley SC Jr (2010) Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. *Circulation* 121:519–528. doi:[10.1161/CIRCULATIONAHA.109.883777](https://doi.org/10.1161/CIRCULATIONAHA.109.883777)
 275. Silver DP, Livingston DM (2001) Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. *Mol Cell* 8:233–243
 276. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. *Pharmacol Rep* 61:154–171
 277. Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, Tymitz KM, Penninger JM, Molkentin JD (2001) Temporally

- regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. *Circ Res* 89:20–25
278. Stansfield WE, Rojas M, Corn D, Willis M, Patterson C, Smyth SS, Selzman CH (2007) Characterization of a model to independently study regression of ventricular hypertrophy. *J Surg Res* 142:387–393. doi:[10.1016/j.jss.2007.01.037](https://doi.org/10.1016/j.jss.2007.01.037)
 279. Stock JH, Keller MD, Sharma S, Pavcnik D, Shiota T, Sahn DJ (1997) Transballoon intravascular ultrasound imaging during balloon angioplasty in animal models with coarctation and branch pulmonary stenosis. *Circulation* 95:2354–2357
 280. Sun ZJ, Zhang ZE (2005) Historic perspectives and recent advances in major animal models of hypertension. *Acta Pharmacol Sin* 26:295–301. doi:[10.1111/j.1745-7254.2005.00054.x](https://doi.org/10.1111/j.1745-7254.2005.00054.x)
 281. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC, Kuhn CM, Rebuffe-Scrive M (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. *Metabolism* 44:645–651
 282. Sussman MA, Welch S, Walker A, Klevitsky R, Hewett TE, Price RL, Schaefer E, Yager K (2000) Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. *J Clin Invest* 105:875–886. doi:[10.1172/JCI8497](https://doi.org/10.1172/JCI8497)
 283. Suzuki M, Carlson KM, Marchuk DA, Rockman HA (2002) Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy. *Circulation* 105:1824–1829
 284. Szenczi O, Kemecei P, Holthuijsen MF, van Riel NA, van der Vusse GJ, Pacher P, Szabo C, Kollai M, Ligeti L, Ivanics T (2005) Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. *Biochem Pharmacol* 69:725–732. doi:[10.1016/j.bcp.2004.11.023](https://doi.org/10.1016/j.bcp.2004.11.023)
 285. Takahashi S, Denvir MA, Harder L, Miller DJ, Cobbe SM, Kawakami M, MacFarlane NG, Okabe E (1998) Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca²⁺ release from sarcoplasmic reticulum and contractile protein function in ‘chemically-skinned’ rabbit ventricular trabeculae. *Jpn J Pharmacol* 76:405–413
 286. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA (2000) Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. *Circ Res* 86:1218–1223
 287. Takemura G, Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. *Prog Cardiovasc Dis* 49:330–352. doi:[10.1016/j.pcad.2006.10.002](https://doi.org/10.1016/j.pcad.2006.10.002)
 288. Takemura G, Miyata S, Kawase Y, Okada H, Maruyama R, Fujiwara H (2006) Autophagic degeneration and death of cardiomyocytes in heart failure. *Autophagy* 2:212–214
 289. Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T (2006) Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. *J Mol Cell Cardiol* 41:989–997. doi:[10.1016/j.yjmcc.2006.07.019](https://doi.org/10.1016/j.yjmcc.2006.07.019)
 290. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. *Nat Med* 11:214–222. doi:[10.1038/nm1175](https://doi.org/10.1038/nm1175)
 291. Taniyama Y, Walsh K (2002) Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. *J Mol Cell Cardiol* 34:1241–1247
 292. Teerlink JR, Pfeffer JM, Pfeffer MA (1994) Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. *Circ Res* 75:105–113
 293. Terrand J, Xu B, Morrissey S, Dinh TN, Williams S, Chen QM (2011) p21(WAF1/Cip1/Sdi1) knockout mice respond to doxorubicin with reduced cardiotoxicity. *Toxicol Appl Pharmacol*. doi:[10.1016/j.taap.2011.08.024](https://doi.org/10.1016/j.taap.2011.08.024)
 294. Toischer K, Rokita AG, Unsold B, Zhu W, Kararigas G, Sossalla S, Reuter SP, Becker A, Teucher N, Seidler T, Grebe C, Preuss L, Gupta SN, Schmidt K, Lehnart SE, Kruger M, Linke WA, Backs J, Regitz-Zagrosek V, Schafer K, Field LJ, Maier LS, Hasenfuss G (2010) Differential cardiac remodeling in preload versus afterload. *Circulation* 122:993–1003. doi:[10.1161/CIRCULATIONAHA.110.943431](https://doi.org/10.1161/CIRCULATIONAHA.110.943431)
 295. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T (1992) Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. *Pharmacol Rev* 44:103–150
 296. Towbin JA, Bowles NE (2002) The failing heart. *Nature* 415:227–233. doi:[10.1038/415227a](https://doi.org/10.1038/415227a)
 297. Tsuji T, Del Monte F, Yoshikawa Y, Abe T, Shimizu J, Nakajima-Takenaka C, Taniguchi S, Hajjar RJ, Takaki M (2009) Rescue of Ca²⁺ overload-induced left ventricular dysfunction by targeted ablation of phospholamban. *Am J Physiol Heart Circ Physiol* 296:H310–317. doi:[10.1152/ajpheart.00975.2008](https://doi.org/10.1152/ajpheart.00975.2008)
 298. Ungerer M, Parruti G, Bohm M, Puzicha M, DeBlasi A, Erdmann E, Lohse MJ (1994) Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. *Circ Res* 74:206–213
 299. Usui S, Yao A, Hatano M, Kohmoto O, Takahashi T, Nagai R, Kinugawa K (2006) Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. *Circ J* 70:1208–1215
 300. Van den Berg DT, de Kloet ER, de Jong W (1994) Central effects of mineralocorticoid antagonist RU-28318 on blood pressure of DOCA-salt hypertensive rats. *Am J Physiol* 267:E927–E933
 301. Van den Bergh A, Flameng W, Herijgers P (2006) Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. *Eur J Heart Fail* 8:777–783. doi:[10.1016/j.ejheart.2006.03.001](https://doi.org/10.1016/j.ejheart.2006.03.001)
 302. van den Meiracker AH (2002) Endothelins and venous tone in DOCA-salt hypertension. *J Hypertens* 20:587–589
 303. Vicart P, Caron A, Guicheney P, Li Z, Prevost MC, Faure A, Chateau D, Chapon F, Tome F, Dupret JM, Paulin D, Fardeau M (1998) A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. *Nat Genet* 20:92–95. doi:[10.1038/1765](https://doi.org/10.1038/1765)
 304. Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL (1997) Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. *Proc Natl Acad Sci USA* 94:9320–9325
 305. Wakisaka Y, Niwano S, Niwano H, Saito J, Yoshida T, Hirasawa S, Kawada H, Izumi T (2004) Structural and electrical ventricular remodeling in rat acute myocarditis and subsequent heart failure. *Cardiovasc Res* 63:689–699. doi:[10.1016/j.cardiores.2004.04.020](https://doi.org/10.1016/j.cardiores.2004.04.020)
 306. Wang QD, Bohlooly YM, Sjoquist PO (2004) Murine models for the study of congestive heart failure: Implications for understanding molecular mechanisms and for drug discovery. *J Pharmacol Toxicol Methods* 50:163–174. doi:[10.1016/j.vascn.2004.05.005](https://doi.org/10.1016/j.vascn.2004.05.005)
 307. Wang X, Ren B, Liu S, Sentex E, Tappia PS, Dhalla NS (2003) Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. *J Appl Physiol* 94:752–763. doi:[10.1152/japplphysiol.00248.200294/2/752](https://doi.org/10.1152/japplphysiol.00248.200294/2/752)
 308. Wang X, Sentex E, Saini HK, Chapman D, Dhalla NS (2005) Upregulation of beta-adrenergic receptors in heart failure due to volume overload. *Am J Physiol Heart Circ Physiol* 289:H151–159. doi:[10.1152/ajpheart.00066.2005](https://doi.org/10.1152/ajpheart.00066.2005)

309. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH (1994) Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. *Circulation* 90:1410–1422
310. Werchan PM, Summer WR, Gerdes AM, McDonough KH (1989) Right ventricular performance after monocrotaline-induced pulmonary hypertension. *Am J Physiol* 256:H1328–H1336
311. West MB, Rokosh G, Obal D, Velayutham M, Xuan YT, Hill BG, Keith RJ, Schrader J, Guo Y, Conklin DJ, Prabhu SD, Zweier JL, Bolli R, Bhatnagar A (2008) Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. *Circulation* 118:1970–1978. doi:[10.1161/CIRCULATIONAHA.108.791533](https://doi.org/10.1161/CIRCULATIONAHA.108.791533)
312. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S (2001) Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphq/Galphi1 in cardiomyocytes. *Nat Med* 7:1236–1240. doi:[10.1038/nm1101-1236](https://doi.org/10.1038/nm1101-1236)
313. Wilson KM, Sumners C, Hathaway S, Fregly MJ (1986) Mineralocorticoids modulate central angiotensin II receptors in rats. *Brain Res* 382:87–96
314. Wood P, Piran S, Liu PP (2011) Diastolic heart failure: progress, treatment challenges, and prevention. *Can J Cardiol* 27:302–310. doi:[10.1016/j.cjca.2011.02.008](https://doi.org/10.1016/j.cjca.2011.02.008)
315. Wu JC, Nasser BA, Bloch KD, Picard MH, Scherrer-Crosbie M (2003) Influence of sex on ventricular remodeling after myocardial infarction in mice. *J Am Soc Echocardiogr* 16:1158–1162. doi:[10.1067/S0894-7317\(03\)00648-5](https://doi.org/10.1067/S0894-7317(03)00648-5)
316. Xiao CY, Chen M, Zsengeller Z, Li H, Kiss L, Kollai M, Szabo C (2005) Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. *J Pharmacol Exp Ther* 312:891–898. doi:[10.1124/jpet.104.077164](https://doi.org/10.1124/jpet.104.077164)
317. Xin HB, Senbonmatsu T, Cheng DS, Wang YX, Copello JA, Ji GJ, Collier ML, Deng KY, Jeyakumar LH, Magnuson MA, Inagami T, Kotlikoff MI, Fleischer S (2002) Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. *Nature* 416:334–338. doi:[10.1038/416334a](https://doi.org/10.1038/416334a)
318. Yamada T, Matsumori A, Wang WZ, Ohashi N, Shiota K, Sasayama S (1999) Apoptosis in congestive heart failure induced by viral myocarditis in mice. *Heart Vessels* 14:29–37
319. Yamori Y (1991) Overview: studies on spontaneous hypertension-development from animal models toward man. *Clin Exp Hypertens A* 13:631–644
320. Yang S, Su L, Wang Z, Liu Z, Kang Y, Lei J (2011) Comparative study on repairing rabbit radius segmental defects with two different proportions of chitosan combined with allogeneic morselized bone. *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi* 25:877–883
321. Yano M, Kobayashi S, Kohno M, Doi M, Tokuhisa T, Okuda S, Suetsugu M, Hisaoka T, Obayashi M, Ohkusa T, Matsuzaki M (2003) FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. *Circulation* 107:477–484
322. Yoo B, Lemaire A, Mangmool S, Wolf MJ, Curcio A, Mao L, Rockman HA (2009) Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. *Am J Physiol Heart Circ Physiol* 297:H1377–1386. doi:[10.1152/ajpheart.00504.2009](https://doi.org/10.1152/ajpheart.00504.2009)
323. Yoshida M, Ohkusa T, Nakashima T, Takanari H, Yano M, Takemura G, Honjo H, Kodama I, Mizukami Y, Matsuzaki M (2011) Alterations in adhesion junction precede gap junction remodelling during the development of heart failure in cardiomyopathic hamsters. *Cardiovasc Res* 92:95–105. doi:[10.1093/cvr/cvr182](https://doi.org/10.1093/cvr/cvr182)
324. Zbinden G, Bagdon RE (1963) Isoproterenol-induced heart necrosis, an experimental model for the study of Angina Pectoris and Myocardial Infarct. *Rev Can Biol* 22:257–263
325. Zbinden G, Moe RA (1969) Pharmacological studies on heart muscle lesions induced by isoproterenol. *Ann N Y Acad Sci* 156:294–308
326. Zhou YY, Song LS, Lakatta EG, Xiao RP, Cheng H (1999) Constitutive beta2-adrenergic signalling enhances sarcoplasmic reticulum Ca²⁺ cycling to augment contraction in mouse heart. *J Physiol* 521(Pt 2):351–361
327. Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. *Circulation* 105:1387–1393
328. Zisa D, Shabbir A, Mastro M, Suzuki G, Lee T (2009) Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells. *Am J Physiol Regul Integr Comp Physiol* 297:R1503–1515. doi:[10.1152/ajpregu.00227.2009](https://doi.org/10.1152/ajpregu.00227.2009)